Stockwinners Market Radar for April 27, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:05 EDT Gatos Silver announces temporary suspension of blasting permit at CLG mine - Gatos Silver "announced the temporary suspension of mine operations as a result of a temporary regulatory suspension of the explosive and blasting permit at the Cerro Los Gatos Mine, or CLG. The Mexican Ministry of Defense, who regulates all explosives permits in Mexico, temporarily suspended CLG's explosive and blasting permit on April 21, 2022, following a blasting incident during underground development activities where two blasts were detonated prematurely. There were no physical injuries as a result of the incident, and no significant damage to equipment or infrastructure. Gatos Silver considers the safety of our employees of critical importance, and a thorough investigation of CLG's blasting procedures is being conducted. The processing plant has continued to operate normally since April 21, 2022, and will shut down on April 28, 2022 for scheduled maintenance activities. Non-production related activities in the mine are continuing normally."

18:23 EDT Mattel CEO says 'all of our factories are fully operational' - Ynon Kreiz is speaking on CNBC's Mad Money.

17:50 EDT Hersha Hospitality reports Q1 hotel portfolio occupancy of 58% - CEO Jay Shah says: "In addition to the continued outperformance of our resort markets, especially in March, we were very encouraged by the increased demand in our urban markets. Our portfolio registered a 31% increase in urban RevPAR in the back half of the month vs. the front half, and that demand has carried into April. While we delivered outsized growth across all of our urban portfolio, our biggest gains were in Philadelphia, Washington DC, and Manhattan. Ongoing dialogue with our corporate accounts indicates return to office and business travel should accelerate in the second quarter and will be further supplemented by renewed small group, as well as in person training programs. We expect these trends will drive further group and business transient demand during the summer."

17:40 EDT Mattel says will not comment on press reports and speculation - Mattel Head of Investor Relations states: "We will not be commenting on press reports and speculation that have come out over the past 24 hours. We are focused on executing our strategy to grow Mattel's IP-driven toy business and expand our entertainment offering." Note: Last night, The Wall Street Journal reported that Mattel has held 'informal talks" with private equity firms that include Apollo Global Management and L Catterton about a potential sale.

17:38 EDT Meta Platforms says still expects targeting, measurement headwinds from IOS 15 - Says global MAUs will be affected by shutdown in Russia. Says some of Russia MAUs are counted in Q1 numbers and they won't be in Q2. Says global MAUs will be flat to down sequentially.

17:28 EDT Meta Platforms says planning to slow the pace on some investments - Says goal is to generate sufficient operating growth to fund investment in Reality Labs. Says short form video is growing very quickly Says Reels makes up 20% of the time people spend on Instagram. Says more of Feed is recommended by AI. Says people will increasingly rely on AI-based discovery engines. Says focused on growing Reels. Says managing headwinds from signal loss. Says the next focus for metaverse will be glowing the community. Says best Horizon Worlds experience will be on virtual and eventually augmented reality platforms. Says working to improve ad situation. Comments taken from Q1 earnings conference call.

17:17 EDT Home Bancshares raises quarterly dividend to 16.5c from 14c per share - The dividend is payable June 8, 2022, to shareholders of record May 18, 2022.

17:12 EDT Ford says accelerating transformation plan - Says will continue to be very aggressive in recruiting talent. Says crafting EV future product pipeline. Says EV designs will be progressive and won't be electric versions of current line up. Says persistent supply chain constraints continue to impact the business. Expects EVs to account for 50% of global sales by 2030. Comments taken from Q1 earnings conference call.

17:07 EDT Methanex raises quarterly dividend to 14.5c from 12.5c per share - The increased dividend will apply to the dividend payable on June 30, 2022 to holders of common shares of record on June 16, 2022.

16:56 EDT Color Star Technology receives extension to meet minimum bid price requirement - Color Star Technology received a letter from Nasdaq on April 26 notifying the company that it is eligible for an additional 180 calendar day period, or until October 24 to regain compliance with the Nasdaq's minimum $1 bid price per share requirement. The company was first notified by Nasdaq of its failure to maintain a minimum bid price of $1.00 per share for 30 consecutive trading days under Nasdaq Listing Rules on October 27, 2021, and was given until April 25, 2022 to regain compliance. The company did not regain compliance with the minimum $1 bid price per share requirement during the first 180-calendar-day compliance period and has submitted the written notice of its intention to cure the deficiency during the second compliance period. If at any time before October 24, 2022, the bid price of the company's ordinary shares closes at or above $1 per share for a minimum of 10 consecutive trading days, the company will regain compliance with the Nasdaq Listing Rules, and the matter will be closed.

16:49 EDT SQZ Biotechnologies gets FDA fast-track designation for SQZ-PBMC-HPV - SQZ Biotechnologies "announced that the FDA has granted Fast Track Designation for the company's lead cell therapy candidate, SQZ-PBMC-HPV, for the treatment of HPV16+ advanced or metastatic solid tumors. Data presented at the ESMO Immuno-Oncology Congress 2021 has shown that the company's lead APC cell therapy candidate induced radiographic, symptomatic and immune response as monotherapy in a post-checkpoint HPV16+ solid tumor patient. The company continues to enroll patients in its highest dose monotherapy cohort and is simultaneously enrolling patients for combination therapy in the company's Phase 1/2 SQZ-PBMC-HPV-101 clinical trial."

16:49 EDT Statera to sell naltrexone, met-enkephalin rights to Immune Therapeutics - Statera Biopharma announced that the company entered into a non-binding term sheet with respect to a strategic agreement with Immune Therapeutics, a drug development and commercialization company, to sell Statera's rights to naltrexone and met-enkephalin. The transaction is contingent upon negotiation of a definitive agreement and satisfaction of a number of closing conditions, including a contingency on Immune Therapeutics financing. Under the anticipated terms of the agreement, Statera will receive an initial $2M upfront payment and 5% of the issued and outstanding stock of Immune Therapeutics. Additionally, Statera will receive payments for achievement of revenue-based milestones, new indications and royalties, Crohn's disease and COVID-19 indications and regulatory approvals, as well as any other payments from Immune Therapeutics in exchange for Statera's rights to any product containing low-dose naltrexone as an active ingredient. Potential indication payments will include asthma, multiple sclerosis, HIV and chemotherapy. In aggregate, this transaction has the ability to generate over $400M in non-dilutive payments to Statera.

16:44 EDT Valaris announces sale of jackups VALARIS 113 and 114 for $125M - Valaris "announced that it has sold heavy duty modern jackups VALARIS 113 and 114 to ADES Saudi Limited for a total of $125M. VALARIS 113 and 114 are PPL Pacific Class 400 jackups, both delivered in 2012. Both rigs have been stacked in the Philippines since they completed their last contracts in late 2015."

16:43 EDT ASGN CFO Ed Pierce to step down - ASGN "also announced that Executive Vice President and CFO, Ed Pierce, will be stepping down as CFO this coming August and will remain in a strategic role through the first quarter of 2023. As part of the Company's long-term succession planning, ASGN and its Board of Directors have selected Marie Perry, an accomplished CFO and proven finance industry leader, as Mr. Pierce's successor as CFO of the Company."

16:39 EDT Trinseo records estimated liability of $36M in styrene monomer E.U. activity - The company states: "In 2018, a subsidiary of Trinseo received a Request for Information from the European Commission Directorate General for Competition related to styrene monomer commercial activity in the European Economic Area, as well as subsequent requests for information. Trinseo has fully responded to all information requests from the European Commission and continues to fully cooperate. As a result of further developments in this matter, in the first quarter of 2022, Trinseo recorded a reserve for an estimated liability of $36M."

16:38 EDT Y-mAbs Therapeutics announces Dr. Claus Moller has stepped down as CEO - Y-mAbs Therapeutics announced the following executive management changes: Dr. Claus Moller has stepped down from his positions as Chief Executive Officer and Board Member effective immediately. Thomas Gad, the Company's Founder, Chairman and President has assumed the role of Interim CEO and Board Member. In addition, Mr. Gad has stepped down as Chairman and Dr. Jim Healy, current Board Member and Chair of the Compensation Committee, has been appointed as Chairman of the Board. The Board has begun a search for Dr. Moller's successor. Dr. Healy said, "On behalf of the Board, we thank Claus for his service and many accomplishments during his tenure as CEO. The Company has made great strategic, commercial, and operational progress. We wish Claus the very best. Claus has assembled a talented and highly capable leadership team, which will ensure continuity while we conduct a search for a permanent replacement."

16:38 EDT Cheesecake Factory sees Q2-to-date SSS up 8.2% - The company states: "As of today, indoor dining capacity restrictions have been lifted for all of the Company's restaurants across all its concepts. Fiscal 2022 second quarter-to-date through April 26th comparable sales for The Cheesecake Factory restaurants increased approximately 8.2% year-over-year, supported by approximately 25% off-premise sales mix. The Company now expects to open as many as 15 to 16 new restaurants in fiscal 2022, including as many as four Cheesecake Factory restaurants, four to five North Italia restaurants, and as many as seven FRC restaurants, including three to four Flower Child locations. This includes a Flower Child which opened subsequent to first quarter-end in Fort Worth. In addition, in fiscal 2022 the Company expects one Cheesecake Factory restaurant to open internationally under a licensing agreement."

16:32 EDT CoStar Group says LoopNet had 'record-breaking' quarter for site traffic in Q1 - CoStar Group announced that LoopNet experienced a record-breaking quarter for site traffic in the first quarter of 2022. "Traffic is trending up and LoopNet is further establishing itself as the name brand for commercial real estate property searches among both tenants and investors," said David Mele, President of LoopNet. "We experienced an unprecedented start to 2022, following a strong 2021 in which the site's year-over-year direct traffic increased by 56%." January, February, and March of 2022 each recorded the highest traffic numbers in the network's history, totaling over 31,375,000 unique visitors for the quarter.

16:30 EDT Helmerich & Payne sees FY22 gross CapEx $250M-$270M - Gross capital expenditures are still expected to be approximately $250 to $270 million; approximately 50% expected for maintenance, including tubular purchases, roughly 35% expected for skidding to walking conversions and approximately 15% for corporate and information technology. Ongoing asset sales include reimbursements for lost and damaged tubulars and sales of other used drilling equipment that offset a portion of the gross capital expenditures and are still expected to total approximately $45 million in fiscal year 2022.

16:23 EDT Synopsys to acquire WhiteHat Security from NTT for $330M in cash - Synopsys announced that it has signed a definitive agreement to acquire WhiteHat Security, a provider of application security Software-as-a-Service. The addition of WhiteHat Security will provide Synopsys with significant SaaS capabilities and market-segment-leading dynamic application security testing technology to strengthen what is considered one of the industry's broadest application security testing portfolio. Synopsys and WhiteHat Security, which was acquired by NTT Security Corporation in 2019, share a vision for delivering SaaS-based security testing solutions and building security into the software development lifecycle. Under the terms of the transaction, Synopsys will pay approximately $330M in cash. The transaction is subject to regulatory review and customary closing conditions and is expected to close in Synopsys' fiscal Q3 2022. Based on its preliminary review, Synopsys currently expects the acquisition to be roughly neutral to FY2022 non-GAAP earnings per share.

16:20 EDT PayPal CEO 'pleased' Q1 results exceeded guidance - President and CEO Dan Schulman said: "I'm pleased our first quarter results exceeded our guidance on revenue and earnings, and we continue to grow faster than the rate of ecommerce. We have much to be proud of but we know we can continue to do even better. We are fortunate to have the opportunity to shape the future of the digital economy by transforming financial services and commerce."

16:17 EDT PayPal reports Q1 TPV $323B, up 13% and 15% on FXN basis

16:11 EDT Meta Platforms up 9% to $191.39 after Q1 earnings beat - Meta Platforms shares are up $16.44, or 9%, to $191.39 in after-hours trading.

16:10 EDT C.H. Robinson to 'continue to benefit from product and technology investments' - The company states: "As questions linger about the impact on global economic growth from the Russian invasion of Ukraine, higher energy prices and inflationary pressures, among other impacts, we believe that our global suite of multimodal services, our growing digital platform, and our resilient and flexible non-asset-based business model will continue to deliver strong financial results through the cycle. We will continue to benefit from our product and technology investments while delivering on opportunities to integrate our services to help our customers solve their complex global supply chain issues. We are uniquely positioned to orchestrate end-to-end supply chain success for our customers and to help them not only navigate uncertain market conditions, but to succeed in doing so. One of the core values we live by is to evolve constantly. To advance our industry leadership in a more digital environment, we are evolving to a product-led organization by reorienting the intersection of our growth strategy and our engineering and technology teams with the needs of our customers and carriers, and we'll continue to differentiate ourselves in the market by having great people that our customers can rely on. I'm excited by the initial results from the enhancements that were rolled out in February for our Navisphere Carrier product. We'll continue to build on our customer-centric commitment by continuing to invest in smart, customer and carrier-focused products, and we'll launch several new products that we believe will benefit our customers and carriers as we continue to build out the most powerful supply chain platform."

16:10 EDT Meta lowers 2022 total expenses view to $87B-$92B - Meta said: "We expect 2022 total expenses to be in the range of $87-92 billion, lowered from our prior outlook of $90-95 billion. We expect 2022 expense growth to be driven primarily by the Family of Apps segment, followed by Reality Labs. We expect 2022 capital expenditures, including principal payments on finance leases, to be in the range of $29-34 billion, unchanged from our prior estimate. Absent any changes to U.S. tax law, we expect our full-year 2022 tax rate to be above the first quarter rate and in the high teens."

16:09 EDT Canadian Pacific reports Q1 operating ratio 70.9% vs. 60.2% a year ago - Adjusted OR increased by 1,130 basis points to 69.8%.

16:08 EDT Meta reports Facebook MAUs of 2.94B as of March 31, up 3% year-over-year - Meta Platforms reports family daily active people, or DAP, was 2.87 billion on average for March 2022, an increase of 6% year-over-year. Reports family monthly active people, or MAP, was 3.64 billion as of March 31, 2022, an increase of 6% year-over-year. Reports Facebook daily active users, or DAUs, were 1.96 billion on average for March 2022, an increase of 4% year-over-year. Facebook monthly active users, or MAUs, were 2.94 billion as of March 31, 2022, an increase of 3% year-over-year. Reports in the first quarter of 2022, ad impressions delivered across its Family of Apps increased by 15% year-over-year and the average price per ad decreased by 8% year-over-year.

16:08 EDT Ford: Scaling of EVs on track to 600,000 units by late 2023

16:07 EDT Ford continues to see FY22 adjusted EBIT $11.5B-$12.5B - Continues to anticipate full-year 2022 adjusted EBIT of $11.5 billion to $12.5 billion, up 15% to 25% from 2021, including improvement in operations outside North America.

16:06 EDT Pinterest reports Q1 global MAUs down 9% y/y to 433M

16:00 EDT Canterbury Park trading resumes

15:50 EDT Nabors sees increase in Lower 48 rig count of 6-7 rigs in Q2 over Q1 average - In U.S. Drilling, Nabors expects a Q2 increase in average Lower 48 rig count of 6 to 7 rigs over the first quarter average, Lower 48 adjusted gross margin per day of approximately $8,500, reflecting a significant increase in average daily revenue from the strengthening of our leading-edge dayrates, somewhat offset by higher labor expenses and inflation, and Offshore slightly above the first quarter levels and higher average dayrates in Alaska. CEO Anthony Petrello said, "Industry fundamentals in the Lower 48, and rig counts in particular, have improved dramatically over the last several quarters. Increasing utilization is driving improvement in our financial metrics and we are now on the path toward significant pricing power. With the backdrop of the constructive commodity price outlook, we expect Nabors' Lower 48 rig utilization and financial performance to accelerate materially over the balance of 2022. These prospects are augmented by growing adoption of our technology portfolio, which enables operators to improve their production profiles and limit their per-barrel costs. Given the positive signals coming from our international markets, we are poised for growth across the Company. That should enable us to make further progress improving our financial position."

14:54 EDT Vuzix teamd Swith Ohana One, a global surgical training nonprofit organization - Vuzix announced that it has collaborated with Ohana One, a global surgical training nonprofit organization whose mission is to cultivate high-quality surgical and anesthesia programs in developing areas around the world today, and TeleVU, an Ontario technology company offering innovative AR, AI and IoT solutions with a special focus on healthcare, to provide critical support to medical personnel in war-torn Ukraine. Doctors and other medical professionals there have been overwhelmed by the large number of military and civilian casualties encountered since Russia first invaded the country on February 24th. For its part, Vuzix has donated a number of M400 smart glasses, which will run TeleVU software and be administered through Ohana One's ongoing borderless mentor/mentee effort.

14:33 EDT Carvana trading halted, volatility trading pause

14:25 EDT Beyond Meat trading resumes

14:21 EDT Archimedes Tech SPAC Partners Company (Units) trading resumes

14:15 EDT North American rail traffic fell 5.8% for the week ending April 23 - The Association of American Railroads or AAR reported U.S. rail traffic for the week ending April 23. For this week, total U.S. weekly rail traffic was 498,011 carloads and intermodal units, down 7.4 percent compared with the same week last year. Total carloads for the week ending April 23 were 229,044 carloads, down 4.5 % compared with the same week in 2021, while U.S. weekly intermodal volume was 268,967 containers and trailers, down 9.8% compared to 2021. Two of the 10 carload commodity groups posted an increase compared with the same week in 2021. They were motor vehicles and parts, up 1,939 carloads, to 13,250; and farm products excl. grain, and food, up 655 carloads, to 16,260. Commodity groups that posted decreases compared with the same week in 2021 included coal, down 6,010 carloads, to 57,894; grain, down 2,351 carloads, to 23,106; and metallic ores and metals, down 1,959 carloads, to 22,259. North American rail volume for the week ending April 23, on 12 reporting U.S., Canadian and Mexican railroads totaled 328,525 carloads, down 3.5% compared with the same week last year, and 357,139 intermodal units, down 7.8% compared with last year. Total combined weekly rail traffic in North America was 685,664 carloads and intermodal units, down 5.8%. North American rail volume for the first 16 weeks of 2022 was 10,673,122 carloads and intermodal units, down 4 percent compared with 2021. Publicly traded companies in the space include CSX (CSX), Canadian National (CNI), Canadian Pacific (CP), Kansas City Southern (KSU), Norfolk Southern (NSC) Union Pacific (UNP) Trinity Industries Greenbrier FreightCar America (RAIL) and Wabtec (WAB).

13:42 EDT TotalEnergies to book $4.1B impairment in Q1 for Arctic LNG 2 project - TotalEnergies noted that on March 22, the company announced that, given the uncertainty created by the technological and financial sanctions on the ability to carry out the Arctic LNG 2 project currently under construction and their probable tightening with the worsening conflict, TotalEnergies SE had decided to no longer book proved reserves for the Arctic LNG 2 project. Since then, on April 8, new sanctions have effectively been adopted by the European authorities, notably prohibiting export from European Union countries of goods and technology for use in the liquefaction of natural gas benefitting a Russian company. "It appears that these new prohibitions constitute additional risks on the execution of the Arctic LNG 2 project. As a result, TotalEnergies has decided to record in its accounts, as of March 31, 2022, an impairment of $4.1B, concerning notably Arctic LNG 2," the company stated.

12:23 EDT Invesco REIT acquires self-storage property, terms not disclosed - Invesco Real Estate Income Trust announced it acquired a 100% interest in a 52,275 square foot, 491-unit self-storage facility located at 3975 University Parkway in Winston-Salem, North Carolina. Developed in 2008, the climate-controlled property is 99.1% leased and located less than 1.5 miles away from Wake Forest University. Winston-Salem has a growing population and is home to the headquarters of notable corporations, including Hanes Brands, Krispy Kreme Doughnuts, and Lowes Foods.

12:14 EDT Digital World jumps after Musk highlights Truth's App Store top spot - Shares of Digital World Acquisition (DWAC), the blank-check company that has agreed to a deal to bring former president Donald Trump's Truth Social public, are soaring after Elon Musk last night tweeted out a screen shot showing that Truth Social is the top free app on the Apple Store, besting Twitter (TWTR) at number two and TikTok at five. Shares of Digital World Acquisition, which had been falling following Musk's agreement to acquire Twitter, are up 20%, or $8.06, to $48.86 in midday trading.

12:01 EDT ProShares UltraShort Bloomberg Natural Gas falls -10.8% - ProShares UltraShort Bloomberg Natural Gas is down -10.8%, or -$1.07 to $8.85.

12:01 EDT NCR Corp. falls -24.1% - NCR Corp. is down -24.1%, or -$9.02 to $28.34.

12:00 EDT Gelesis rises 13.6% - Gelesis is up 13.6%, or 60c to $5.04.

11:34 EDT CynergisTek signs two contracts totaling $416,000 - CynergisTek increases its IT Audit and Privacy professional services support for a global leader in medical device manufacturing and a Real Estate Investment Trust Firm located in the Midwest. CynergisTek has signed two contracts totaling $416k to support both clients with professional services. There was a 37% increase to the medical device manufacturer's contract for expanded, ongoing data protection and privacy risk advisory support services. CynergisTek's IT Audit Group has also signed a six-figure contract with a real estate investment firm to provide IT General Computer Control Audit services, which will provide the client with high-level assessments of their IT system operations and security controls, as well as recommendations for functional improvement.

11:17 EDT GDIT awarded $661.6M digital modernization contract for the EPA - General Dynamics Information Technology announced that it was awarded the Environmental Protection Agency Managed Application, Infrastructure, Networking, Enterprise, and Security Services task order by the General Services Administration Federal Systems Integration and Management Center. The task order, awarded in first-quarter 2022, has a total value of $661.6 million with a one-year base plus six one-year option periods. FDIT will provide a full range of services under the EPA MAINES task order to develop and operate the EPA's enterprise IT infrastructure and application platforms. Services will include cloud computing, application platform management, enterprise network and security operations, enterprise identity access management, and cybersecurity.

11:03 EDT Boeing continues to see stable demand in defense and space

10:51 EDT JE Cleantech Holdings Ltd trading resumes

10:48 EDT FDA warns of airway obstruction with Medtronic electromyogram tubes - The Food and Drug Administration said it is evaluating the potential risk of airway obstruction when using silicone-based electromyogram endotracheal tubes from Medtronic. The FDA has received reports describing serious adverse events and deaths for these devices after airway obstruction and ventilation failure. If the tube does not ventilate properly, patients may suffer oxygen deprivation, brain damage, or death, the agency said in a statement. Reference Link

10:46 EDT JE Cleantech Holdings Ltd trading halted, volatility trading pause

10:40 EDT Boeing decision to extend 777-9 into 2025 made 'out of a position of strength'

10:34 EDT PMV Pharmaceuticals to present initial PC14586 Phase 1 data at ASCO - PMV Pharmaceuticals announced that initial clinical data from the Phase 1 dose-escalation portion of the ongoing Phase 1/2 study evaluating PC14586 have been selected for oral presentation at the 2022 American Society of Clinical Oncology, or ASCO, Annual Meeting, to take place June 3-7.

10:25 EDT Lava Therapeutics to present updated LAVA-051 clinical data at ASCO - Lava Therapeutics announced the company will present updated interim data from the dose escalation phase of the ongoing Phase 1/2a clinical trial of LAVA-051 in patients with relapsed or refractory chronic lymphocytic leukemia, or CLL, and multiple myeloma, or MM, at the 2022 American Society of Clinical Oncology, or ASCO, Annual Meeting taking place in Chicago and virtually June 3-7.

10:21 EDT American Water increases dividend 8.7% to 65.5c per share - American Water Works announced that its board of directors increased its quarterly cash dividend payment from 60.25c to 65.5c per share, an increase of 8.7%. The increased quarterly dividend will be payable on June 1, to all shareholders of record as of May 10. The company said it expects to continue its dividend growth at the high end of a 7%-10% range over the long term, with a target dividend payout ratio of between 55%-60% of earnings. "American Water continues to be an industry leader in dividend growth, which is a result of our continued successful execution of key strategic initiatives. We recognize the value of our long history of dividend growth and the role it has played in delivering exceptional shareholder value," said Susan Hardwick, president, CEO and CFO of American Water.

10:06 EDT Elevation Oncology says initial data from Phase 2 CRESTONE study coming at ASCO - Elevation Oncology announced that its abstract highlighting initial data from patients in Cohort 1 of the ongoing Phase 2 CRESTONE study was selected for oral presentation at the upcoming American Society of Clinical Oncology, or ASCO, Annual Meeting, being held June 3-7. CRESTONE is a tumor-agnostic clinical trial evaluating seribantumab in patients with solid tumors that harbor an NRG1 fusion and have progressed after at least one prior line of standard therapy. "We believe seribantumab has the potential to be a best-in-class and differentiated therapy for patients with tumors that harbor NRG1 gene fusions, and we are pleased to have the opportunity to share data with the medical community through an oral presentation at the American Society of Clinical Oncology 2022 Annual Meeting. These genomically defined patients are particularly underserved with no approved targeted therapies currently available. We look forward to presenting initial clinical data from our ongoing Phase 2 clinical trial evaluating seribantumab's ability to address the underlying drivers of tumor growth in this difficult-to-treat patient population," said Shawn M. Leland, PharmD, RPh, Founder and CEO of Elevation Oncology.

10:01 EDT BAE Systems awarded $2.8M contract from the Air Force Research Laboratory - BAE Systems has been awarded a $2.8 million, three-year contract from the Air Force Research Laboratory to develop a new approach to defeat adversaries: by overwhelming them with complexity. As part of the Complexity Modeling in Multiple Domains program, BAE Systems will develop highly complex models to capture the "decision calculus" of an adversary, provide an estimate of how different attacks will affect their ability to respond, and ultimately drive them to the point of indecision.

10:00 EDT RPC, Inc. falls -9.8% - RPC, Inc. is down -9.8%, or -$1.05 to $9.70.

10:00 EDT John Bean Technologies rises 12.0% - John Bean Technologies is up 12.0%, or $12.27 to $114.74.

10:00 EDT SEACOR Marine Holdings rises 14.0% - SEACOR Marine Holdings is up 14.0%, or 93c to $7.58.

09:47 EDT Dana falls -8.4% - Dana is down -8.4%, or -$1.24 to $13.61.

09:47 EDT NCR Corp. falls -25.0% - NCR Corp. is down -25.0%, or -$9.32 to $28.03.

09:47 EDT Constellium rises 10.1% - Constellium is up 10.1%, or $1.58 to $17.23.

09:42 EDT NiSource chief experience officer Violet Sistovaris to retire - NiSource announced that EVP and Chief Experience Officer Violet Sistovaris is retiring after 28 years with the company. Violet joined NiSource in 1994 after being recruited from Centier Bank, where she served as vice president, training and development. Violet will remain with the company until July 1 while a national search is underway for her replacement.

09:40 EDT Astria Therapeutics trading resumes

09:37 EDT Alkermes jumps 11% to $30.23 following Q1 beat

09:35 EDT Tishman Realty, Cross Lake acquire Wyndham Grand Orlando Bonnet Creek - Tishman Realty and Cross Lake Partners announced they have acquired the Wyndham Grand Orlando Bonnet Creek, a 400-room upper upscale hotel located at 14651 Chelonia Parkway in Orlando, Florida. The seller of the hotel was Wyndham Hotels & Resorts. HEI Hotels & Resorts will assume property management of the hotel which was previously managed by the seller. Built in 2011, the 14-story full-service hotel consists of 400 guestrooms, 50,000sf of event space, a resort spa, a fitness center, and multiple food and beverage outlets. The hotel is situated in Bonnet Creek, a private development of four hotels bordered by Walt Disney World on three sides. The hotel is located within two miles of Disney's Hollywood Studies, Epcot, and the Disney Springs entertainment and retail emporium and in close proximity to the other major theme parks including Disney's Magic Kingdom and Universal Studios.

09:33 EDT APT announces $50M commitment to NJ workforce development - Atlantic Power Transmission announces a $50 million commitment to workforce development in New Jersey. The commitment contributes towards creating a workforce hub for the burgeoning offshore wind industry in the Northeast region and the state, addressing one of the recommendations outlined by the New Jersey Offshore Wind Strategic Plan. APT remains committed to this smart, coordinated approach at this critical early stage in the development of the nation's offshore wind market. APT will initiate this investment into the New Jersey workforce upon award of its bids to provide transmission supporting the delivery of 3,600MW of offshore wind power to the existing electrical grid under the New Jersey Offshore Wind SAA Transmission Solicitation initiated by the New Jersey Board of Public Utilities and PJM Interconnection. This funding commitment of $50 million over ten years will support workforce development investment in New Jersey's education, training, and research institutions.

09:30 EDT Astria Therapeutics trading halted, volatility trading pause

09:25 EDT Harley-Davidson says expects supply constraints to continue going forward - Says worked through significant supply chain constraints. Says expects constraints to continue. Says HDMC revenue growth of 6% driven by global motorcycle pricing and growth across P&A and apparel businesses. Says HDFS Operating Income decline of 27% driven by the significant loss reserve release in 2021 and normalization of losses in-line with expectations. Says merger transaction between LiveWire and AEA-Bridges Impact Corporation on track to close in mid-2022. Says global motorcycle pricing and volume growth in P&A offset the negative impact from product mix and FX. Comments taken from Q1 earnings conference call.

09:21 EDT GDS Holdings, YTL partner on 168MW data center development - YTL Power International Berhad and GDS Holdings signed a partnership to co-develop 168MW of data center capacity, across 8 individual data center facilities, at the upcoming YTL Green Data Center Park in Johor, Malaysia. The first phase of the co-development will enter service in 2024. YTL Green Data Center Park is a visionary project initiated by YTL Data Center Holdings, a wholly-owned subsidiary of YTL Power. Located in Kulai, Johor, approximately 30 kilometres from the cities of Johor Bahru and Singapore, it will comprise 500MW of total data center capacity integrated with an equivalent amount of solar power generation. It is the first hyperscale data center campus in Malaysia to be powered by on-site renewable energy. Separate from the co-development with GDS, construction of 72MW of capacity has already commenced on site for other hyperscale customers. With 275 acres dedicated toward data center development, YTL Green Data Center Park in Johor is expected to serve a growing demand in the region for sustainable and cost efficient data center solutions. GDS's presence at the YTL Green Data Center Park will complement its previously announced hyperscale data center projects at Nusajaya Tech Park, Johor and Nongsa Digital Park, Batam, Indonesia.

09:18 EDT Yield10 Bioscience appoints Willie Loh as special commercial, technical advisor - Yield10 Bioscience named Willie Loh, Ph.D., as a special advisor to the Board of Directors and Management of the Company, effective immediately. Dr. Loh previously served as Vice President, Market Development, Global Edible Oils Division at Cargill Incorporated, the global food and agriculture company.

09:17 EDT Osisko Development announces results from annual, special meeting - Osisko Development Corp. announces that, at the annual and special meeting of shareholders held on April 26, 2022, each of the 6 nominees listed in the management information circular filed on April 4, 2022 with the regulatory authorities were elected as directors of the Corporation. Based on the proxies received, PricewaterhouseCoopers, LLP, Chartered Professional Accountants, was appointed as independent auditor of the Corporation for the ensuing year and the directors are authorized to fix its remuneration. Based on the proxies received with respect to the adoption of an ordinary resolution to approve the Corporation's existing Stock Option Plan. Based on the proxies received with respect to the adoption of a special resolution authorizing an amendment to the articles of the Corporation to effect a consolidation of the issued and outstanding common shares of the Corporation for a number to be determined within a range of two and three pre-consolidation common shares and authorizing the directors of the Corporation to determine the final consolidation ratio within such range. Following the annual and special meeting of shareholders of the Corporation, the Board of Directors determined to consolidate its common shares on a 3 for one basis, subject to the receipt of all necessary approvals.

09:14 EDT Bexil Corp announces tender offer - Bexil Corporation announced that it invites its shareholders to tender for $27.50 per share up to an aggregate of 50,000 shares of the Company's common stock. Shareholders may participate in the offer by tendering any or all of their shares, subject to the proration provisions and other limitations of the offer, as described in the offer to purchase. The offer to purchase and withdrawal rights will expire on June 1, 2022 at 5:00 p.m. ET unless the offer to purchase is extended or earlier terminated. The offer to purchase and other tender offer materials are being furnished to shareholders of the Company and also may be obtained at www.Bexil.com. With questions or requests for assistance please call the Company at 212-785-0900 or write to Bexil Corporation, 3814 Route 44, Millbrook, NY 12545, Attn: Secretary. Shareholders may also contact the broker, dealer, commercial bank, or trust company who holds their shares for assistance concerning the offer. The Company's board of directors has approved the offer. However, neither the Company nor the board of directors makes any recommendation as to whether a shareholder should tender or refrain from tendering his or her shares, and neither the Company nor the board of directors has authorized any person to make any such recommendation. Shareholders are urged to evaluate carefully all information contained in the offer to purchase, consult their own investment and tax advisors, and make their own decision whether to tender shares and, if so, how many shares to tender.

09:14 EDT ENGlobal provides update on renewable diesel, SAF plant project - ENG commented on its previously announced project to design and build a renewable diesel and sustainable aviation fuel plant. As first announced on February 22 this year, ENG will utilize its modular execution strategy combined with its standard 6500 bpd plant design and, along with its partners, provide engineering, procurement and construction services for a complete plant designed to produce approximately 100 million gallons of sustainable aviation and diesel fuel per year from renewable feed stocks. This combination benefits their client by reducing the time from final investment decision to first fuel production, reducing cost and increasing accuracy of design and procurement. The project is currently scheduled to be completed within approximately 24 months from FID. Additionally, because this is the second US project of its type under execution by ENG, it will benefit from lessons learned from a similar project as well as by using the same vendors and construction partners. This second US-based plant will utilize licensed process technology from Haldor Topsoe A/S, known as their "HydroFlex" and "Hydrogen Bridge" technologies, to produce fuels with a low carbon footprint. The plant represents an expansion of ENG's renewables project portfolio following its recent successful design, engineering, fabrication and delivery of a modular hydrogen facility valued in excess of $28 million. Assuming the FID is made, ENG expects its scope on the current project to exceed $100 million.

09:12 EDT CareCloud adds CCM service to its digital health portfolio - CareCloud has announced its new offering for chronic care management as part of its growing suite of digital health solutions that help providers enhance patient care and revenue streams. CareCloud Wellness gives practices the means to easily participate in the government's chronic care management, CCM, program, without having to expand operations. CareCloud Wellness is a software-enabled service that extends care to high-risk patients with multiple chronic conditions. This service, which comes at no additional operational expense to the provider, gives physicians increased program eligibility and the opportunity to collect payment for providing in-between appointment services to Medicare, Medicaid, and dual-eligibility patients. "Under today's value-based healthcare model, the Centers for Medicare and Medicaid Services considers the CCM program to be an essential component of care for chronically ill patients. However, providers have found it difficult to capitalize on this program because participation often requires costly operational investment," said CareCloud CEO and President Hadi Chaudhry. "With CareCloud Wellness, we are giving our clients a turnkey solution that enables participation-giving them the ability to create revenue opportunities while improving patient health and experiences."

09:11 EDT XFuels announces milestone LOI to acquire Triple S gas of Dallas, Texas - Xfuels announces it has executed a LOI with Triple S gas of Dallas, Texas in an all-cash deal for consisting of 7 leases, 54 wells and 6 oil batteries in Wichita and Wilbarger counties. Cycle will pay $320,000 dollars plus a 2.5 % capped ORRI to $250,000 dollars. Adjacent to the Triple S leases a neighboring producer has recovered 1.5M barrels of oil as well as 1 mmcf of gas in the same formations. Cycle believes that deeper reserves are also available and can be accessed through deepening the existing wellbores without the added cost of drilling a new well. Michael McLaren, CEO states, "This acquisition is our milestone leap into Texas oil and gas production business and our team is eager to get focused on the project and push these leases to their maximum potential." Mr. McLaren further states, "With our business strategy of Acquire, Restore, Produce and Consolidate these leases fit perfectly into that window where we can apply our world class knowhow and stimulation technologies to maximize the potential of the production."

09:09 EDT TEN, Ltd. announces the sale of 2006-built LR2 product tanker - TEN announced the sale of a 2006-built LR2 aframax tanker, one of the largest product tankers in the world at the time of its construction, to unrelated entities. This sale will generate the company $7.1M of free cash, after the repayment of related debt to be recorded in the second quarter of 2022. "This timely sale depicts our commitment to our stated "Greenship" initiative as it coincides with the recent order of four dual-fuel aframaxes on long-term employment to a significant end-user. As we continue to explore and evaluate future alternatives, similar transactions should be expected," George Saroglou, COO of TEN commented.

09:07 EDT Valmont Ericsson acquire majority interest in 5G infrastructure firm ConcealFab - Valmont Industries announced that it has signed a definitive agreement to acquire a majority interest in Colorado-based ConcealFab, an industry leader in 5G infrastructure and passive intermodulation mitigation solutions. Ericsson, a global leader in 5G technology, will reinvest their ConcealFab equity and hold a minority position in the new company. The strategic partnership with Ericsson to acquire ConcealFab aligns Valmont with a leading provider of innovative 5G infrastructure and PIM mitigation solutions. Founded in 2007 in Colorado Springs, CO., ConcealFab has been recognized as one of the fastest growing companies in the Telecom industry. Their success is a result of their first-to-market innovation, customer-centric fulfillment strategy and ability to design, manufacture and meet ever-changing and specific industry demands. ConcealFab's partnerships with wireless operators, utilities, and major OEMs have also been a key driver in their rapid growth and will continue to support future expansion. Valmont's Telecom strategy is focused on three key objectives: providing vital end-to-end infrastructure products, spreading inclusive. The transaction will be funded with cash on hand, and is expected to be immediately accretive to earnings, with Year-1 revenue of approximately $50M. The transaction is expected to close in the second quarter of 2022 and is subject to customary closing conditions.

09:06 EDT Magellan Midstream announces open season for El Paso pipeline expansion - Magellan Midstream announced the launch of an open season to assess customer interest in firm pipeline capacity on its refined petroleum products pipeline system from the Houston area to El Paso, Texas. Interested customers must submit binding commitments by June 24. The proposed project includes the expansion of a 265-mile pipeline segment between Odessa and El Paso and the use of existing and underutilized pipeline capacity from the Houston area to Odessa. The project would increase Magellan's capability to transport refined petroleum products, such as gasoline and diesel fuel, from Gulf Coast refineries to El Paso, with further shipper optionality to access markets in New Mexico through Magellan's pipeline system, as well as Arizona and Mexico via connections to third-party pipelines. The capital-efficient expansion would increase the capacity of the Odessa-to-El Paso portion of the pipeline by an estimated 15,000 bpd, to a new total capacity of approximately 85,000 bpd. Subject to the results of this open season and receipt of all necessary permits and approvals, the higher capacity could be available by mid-2023 following the addition of incremental pumping capabilities and construction of operational storage at El Paso.

09:05 EDT Avalon GloboCare expands IP portfolio, files 16 new patent applications - Avalon GloboCare announced today that the Company has jointly filed 16 patent applications, co-invented with key strategic partners, including a top-5 U.S. university, a leading education and research center in Europe, as well as a premier multi-national developer of cellular therapies in the field of oncology. Patents were filed with the U.S. Patent and Trademark Office, USPTO, the China National Intellectual Property Administration, CNIPA, and under the Patent Cooperation Treaty, PCT, covering 36 countries. The new intellectual property covers three core patent families: Engineering and bio-manufacturing of novel chimeric antigen receptor, CAR, T-cells related to the mRNA-based Flash-CARTM cellular therapy platform. Soluble, antibody-like cytokine/chemokine decoy receptors derived using the QTY protein design. Novel S-layer coated emulsome technology-derived fusion proteins intended for mucosal vaccine development, which is designed to trigger robust protective immune responses at the predominant sites of pathogen infection. "These latest patent applications solidify and expand our robust IP portfolio, both in the U.S. and internationally," said David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare. "We are especially honored to partner with several leading global academic researchers and institutions in the field of cell therapy, as co-inventors of the technologies. We believe these patent applications will extend our geographic IP protection and are timed to maximize the duration of the patents for decades to come. These patents are within our core competencies in the areas of CAR-T, QTY protein design and S-layer technologies, thereby enhancing our position as a leader in immuno-oncology and cellular medicines. Collectively, we believe each of these patents covers therapies and technologies that target large, addressable markets. They are all supported by strong preclinical data as we rapidly advance towards first-in-human clinical trials."

09:04 EDT Oberon announces commercial availability of rDME/Propane blend - Oberon Fuels announces commercial availability of a new approach to drive down emissions across the propane industry: a blend of propane and Oberon's renewable DME. This blend replaces some of propane's fossil-derived fuel with a renewable one, enabling up to a 60 percent reduction in carbon emissions for this popular fuel used in vehicles, forklifts, farm equipment, backyard grills and outdoor heaters. Beginning today, Oberon partner Suburban Propane Partners is the first company to make this more sustainable blended product available to its customers across Southern California.

09:03 EDT NextNav, Widow Games partner for geolocation authentication for the metaverse - NextNav has partnered with Widow Games. Through the partnership, Widow Games will bring NextNav's 3D geolocation capabilities to their applications, enabling more immersive virtual experiences tied to the real environments of users, and leveraging location verification to validate transactions and interactions in the metaverse. NextNav Pinnacle will be integrated into Widow Games' marquee title, Geopoly, a mobile game that couples buying, upgrading, and selling digital properties tied to the real world with real-time, live virtual events. NextNav Pinnacle will validate the geolocation - including the vertical dimension and timestamp - of users to authenticate attendance, verify transactions, and prevent in-game location-based spoofing. Through geofencing and geolocation, the positioning of specific users in the real world will enable location-based virtual experiences and rewards, authenticate users' presence at virtual events, and facilitate interactions with other users in the same location.

09:01 EDT Riot Blockchain announces 1 GW development in Navarro County, Texas - Riot Blockchain is pleased to announce that it has initiated a large-scale, 1 gigawatt development to expand its Bitcoin mining and hosting capabilities in Navarro County, Texas. The Expansion has begun with the development of an initial 400 megawatts of capacity on a 265-acre site, with immersion-cooled mining and hosting operations expected to commence in July 2023. This first phase of the Expansion includes land acquisition, site preparation, substation development, transmission construction, along with construction of ancillary buildings and four buildings utilizing the Company's immersion-cooling infrastructure and technology. Riot estimates that the total cost of the first phase of the Expansion will be approximately $333 million, which is scheduled to be invested over the remainder of 2022, 2023, and the first quarter of 2024. After completing the first 400 MW phase of the Expansion, future capacity at the site will be expandable by an additional 600 MW to 1,000 MW, or 1 GW, via the 345 kV Navarro switch that is located approximately 1,250 feet away from the site. Riot plans to utilize its strategic partnership with Priority Power an industry leader in Bitcoin mining energy services, to support the Expansion. Priority Power services include managing site development, utility interconnection, power purchase agreements and power load flexibility. The Company's relationship with Priority Power began with the development of Riot's Whinstone US, Inc. facility in Rockdale, Texas, and has been a key partner in its power strategy since. Located approximately one hour south of Dallas, the Expansion site is within two hours of the Whinstone Facility, allowing the Company to leverage its existing talent pool and the proven development capabilities of its experienced employee base. The first 400 MW phase of the Expansion is anticipated to create approximately 270 direct jobs and drive significant positive economic change in Navarro County.

08:51 EDT WiMi Hologram announces technical article on VR tech in stroke patients - WIMI Hologram Academy, working in partnership with the Holographic Science Innovation Center, has written a new technical article describing their exploration of their application of applying VR technology into the treatment for stroke patients' rehabilitation. The company said, "VR technology is gradually expanding its fields of application owing to its rapid development. The integration of VR technology and the treatment in balance function disorder, compared with conventional treatment, demonstrates explicit advantages in the aspects of life quality, feedback and outcomes, thus offering a promising future. Cerebral apoplexy, also known as stroke, or cerebral vascular accident, refers to an acute cerebrovasculardisease lasting more than 24 hours featured with acute or focal brain dysfunction caused by all kinds of vascular causes. Typically it includes cerebral hemorrhage, cerebral infarction, subarachnoid hemorrhage and other diseases. Scientists from WIMI Hologram Academy of WIMI Hologram Cloud have studied the application of virtual reality technology in balance function disorder after cerebral apoplexy. Virtual reality technology uses a computer to simulate the real world and allows the user to experience the virtual world. Compared with traditional rehabilitation training, virtual reality technology is fun, safe and can greatly mobilize the patient's initiative, featuring with competitive advantage in the rehabilitation of balance function, thus providing a new treatment for patients' rehabilitation."

08:45 EDT Conduent announces enhancements to Strataware platform - Conduent announced two new enhancements to its highly configurable Strataware medical bill review platform. Strataware Relatedness and Strataware Rarity add greater efficiency to the bill review process and help workers compensation payers reduce medical spend with proprietary algorithms, advanced logic and automation to ensure that only compensable medical expenses are paid. Strataware Relatedness identifies medical bills which contain ICD diagnosis codes for treatment not related to an injury. Strataware Rarity highlights medical services that are unlikely or rare for a workers compensation claim. Conduent analysis of more than one million medical bills using Relatedness identified nearly 33 percent contained charges for treatment not related to a workplace injury, accident, or illness. An analysis of 2.3 million medical bills using Rarity identified 10 percent of bills contained diagnosis codes for conditions that are rarely treated in workers compensation.

08:43 EDT Vir Biotechnology announces new data from MARCH hepatitis B trial - Vir Biotechnology announced that the company will review its robust hepatitis portfolio, including initial data from the first cohort of the MARCH trial evaluating VIR-2218 in combination with VIR-3434, as well as a new program aimed at chronic hepatitis D. Details will be discussed during Vir's virtual Hepatitis Portfolio R&D Day. "We are pleased to share encouraging data from the MARCH trial, which suggest that VIR-2218 and VIR-3434 are additive in reducing hepatitis B surface antigen, with no drug-related safety signals reported to date - supporting our strategy of combining antivirals with immunomodulators," said George Scangos, Ph.D., Vir's chief executive officer. "We are also excited to announce a new synergistic program that will leverage our differentiated assets to treat hepatitis D, the most aggressive form of viral hepatitis for which there are limited treatment options. Together with the other ongoing combination trials in our pipeline, we believe we have multiple opportunities to achieve meaningful outcomes for both hepatitis B and D." Anticipated Hepatitis Milestones: In 2022, the Company expects to report data from multiple trials for the treatment of chronic hepatitis B virus infection including: Additional data from the Phase 1 monotherapy trial of VIR-3434 and the Phase 2 monotherapy trial of VIR-2218, first half of 2022; Additional data from the Phase 2 trial of VIR-2218 in combination with PEG-IFN-alpha, second half of 2022; Additional data from the first cohort of the Phase 2 MARCH trial evaluating safety, pharmacokinetics and hepatitis B surface antigen suppression, second half of 2022; Initial data from the Phase 2 trial evaluating VIR-2218 in combination with BRII-179, an investigational T cell vaccine, for the potential treatment of chronic HBV infection, led by Brii Biosciences, second half of 2022. Beyond 2022, the Company expects to report: Initial data from the Phase 2 trial evaluating various combinations of VIR-2218, selgantolimod, Gilead's investigational TLR-8 agonist, and nivolumab, an approved PD-1 inhibitor for HBV, first half of 2023; Initial data from the second cohort of the Phase 2 MARCH trial for HBV to determine dose, length of treatment and evaluate triple cocktails, when VIR-3434 is given every four weeks, second half of 2023; Initial data from a Phase 2 viremic trial of VIR-2218 in combination with VIR-3434 in the second half of 2023, following trial initiation in the second half of 2022; Initial data from a Phase 2 trial of VIR-2218 in combination with VIR-3434 for the treatment of HDV in 2023, following trial initiation in the second half of 2022.

08:43 EDT Vivakor awarded contract for sale of asphalt from Utah facility - Vivakor is pleased to announce the signing of a 10-year contract with Hot Oil Transport, a supplier of asphalt materials, which HOT in turn supplies to Southwest Liquid Asphalt & Emulsions, a major supplier of polymerized asphalt in Southern Nevada. Based on the current asphalt wholesale index price for the Rocky Mountain region, this contract could be valued at up to $250 million over the life of the contract, provided that Vivakor is able to ramp up and operate its Vernal, Utah site at full capacity. SLA's largest customer is Las Vegas Paving, one of the largest road construction companies in the state of Nevada, with revenues of more than $500 million annually. Under the Agreement, Vivakor can provide HOT with up to 50,000 tons of ratable asphalt cement from Vivakor's Vernal, Utah, upon completion of anticipated scaled up operations, annually for a period of ten years. Pricing will be based on the asphalt wholesale index price for the Rocky Mountain region at the time of delivery. Based on the current index pricing range of $510 to $600 per ton, this contract could generate between $25 million and $30 million in annual sales once the project is operating at full capacity. To operate at full capacity and take advantage of the maximum opportunity under the contract with HOT, Vivakor estimates it would need to add three additional Remediation Processing Centers, as well as ramp up other required infrastructure, at the Vernal, Utah site, with an estimated total cost of $18 million.

08:41 EDT BTCS adds Kava to its blockchain infrastructure operations - BTCS announces the addition of Kava to its blockchain infrastructure operations. Growing from a $3M Initial Exchange Offering in 2019, Kava is now a $913M layer-1 blockchain protocol with a decentralized lending platform at its core. Kava takes a cross-chain approach to decentralized finance, DeFi. Upon its launch, it became the first DeFi project deployed on the Cosmos blockchain. Instead of just relying on one cryptocurrency, Kava allows its users to leverage and hedge almost any asset that they want, supporting a multitude of different assets. "Kava's cross-chain infrastructure speaks to a major part of the BTCS mission because it runs on two different Proof-of-Stake blockchain networks already supported by our infrastructure operations - Cosmos and Ethereum," Michael Prevoznik, Chief Financial Officer of BTCS, said. In addition to generating revenue by running a Kava validator node, BTCS has completed the technical work to integrate Kava into its planned staking-as-a-service platform once launched.

08:39 EDT WiMi Hologram writes technical article on VR tech in stroke patients - WIMI Hologram Academy, working in partnership with the Holographic Science Innovation Center, has written a new technical article describing their exploration of their application of applying VR technology into the treatment for stroke patients' rehabilitation. The company said, "VR technology is gradually expanding its fields of application owing to its rapid development. The integration of VR technology and the treatment in balance function disorder, compared with conventional treatment, demonstrates explicit advantages in the aspects of life quality, feedback and outcomes, thus offering a promising future. Cerebral apoplexy, also known as stroke, or cerebral vascular accident, refers to an acute cerebrovasculardisease lasting more than 24 hours featured with acute or focal brain dysfunction caused by all kinds of vascular causes. Typically it includes cerebral hemorrhage, cerebral infarction, subarachnoid hemorrhage and other diseases.Scientists from WIMI Hologram Academy of WIMI Hologram Cloud have studied the application of virtual reality technology in balance function disorder after cerebral apoplexy. Virtual reality technology uses a computer to simulate the real world and allows the user to experience the virtual world. Compared with traditional rehabilitation training, virtual reality technology is fun, safe and can greatly mobilize the patient's initiative, featuring with competitive advantage in the rehabilitation of balance function, thus providing a new treatment for patients' rehabilitation. 1. Characteristics of balance function disorder after cerebral apoplexy: As one of the important physiological functions of the human body, balance is related to posture, transfer and motion control. From the mechanical perspective, balance means that an object is subjected to equal forces from all directions so that it can maintain a stable state. While for the balance of the human body, it is more complex than the balance of objects in nature. Balance is the ability of the body to maintain an upright standing posture in different environments and to adjust and maintain itself automatically when moving or subjected to external forces, including reactions such as balance, protective stretching, striding and jumping. Human body depends on balance in daily life, movement and work, and the maintenance of balance is mainly influenced by vestibular system, proprioception, vision, as well as the brain's balancing reflex regulation and muscle strength. Impaired balance is often characterized by unstable sitting and standing, reduced ability in transferring and walking , and increased risk of falls, which can seriously affect daily life and life quality. Statistics show that in recent years, the disability rate of stroke is high, and about 83% of them suffer from balance function disorder, which greatly increases the burden on families and society. Since the improvement of balance is fundamental to the recovery of movement function and daily activities, balance rehabilitation can be particularly important. 2. The application of VR technology in the rehabilitation of balance function disorder after cerebral apoplexy.: 2.1 Comparison between VR technology and conventional rehabilitation treatment: Conventional rehabilitation methods for balance function disorder mainly involve the use of techniques or rehabilitation equipment for gravity center transfer and movement control exercises in different postures, as well as strengthened sensory input through mirror therapy. While techniques such as suspension, core training, and neuromuscular facilitation focus on enhancing core stability and training trunk control, gravity center transfer, and overall movement function. Neurophysiological treatments include movement relearning training methods, proprioceptive neuromuscular facilitation methods, etc. Although these methods to some extent help improve patients' balance and movement functions, the therapeutic effects depend on the therapist's experience and skill level. While for conventional Chinese rehabilitation therapies such as Taijiquan, Baduanjin Exercise and Wuqinxi Exercise, they lack the necessary feedback during training, are prone to causing abnormal movements and injuries. And for equipment-assisted therapies, such as transcranial magnet and balance apparatus, they featured with single movements, lack of fun and objectivity, which make it difficult to mobilize patients' enthusiasm and initiative. Virtual reality technology uses computers to synthesize 3D environment models and apply these models to create and experience virtual worlds. It is a system simulation of multi-source information fusion interactive of 3D dynamic visual and physical behavior that allows users to enter virtual space and interact with objects in the virtual world with the help of scene displays, force/tactile sensing devices, position trackers and other devices to create a realistic experience of being there. Virtual reality technology mainly combines sensory interference training and dual task training to enhance the integration of vestibular sensory information and the organization of vestibular center of stroke patients with hemiplegia by adding virtual reality technology balance training, thus promoting postural stability. The study indicated that by combining virtual reality rehabilitation exercises with conventional rehabilitation training, patients' limb function, neurological function, balance function, as well as their life quality can be effectively improved. 2.2 The application of VR in the rehabilitation of stroke: VR can provide various virtual environments for patients to create immersive feelings and experiences, while also providing technical means for rehabilitation training with key factors such as repetitive exercises, real-time feedback, and motivation maintenance. Through repetitive active training in various environments and movement relearning, it helps accelerate the establishment of collateral circulation and improves neurological deficits, balance function and overall movement function. The study indicated that treatment combined VR technology with conventional rehabilitation training for canoe paddling exercises in subacute stroke patients for 30 minutes per day and three times per week, significant restoration can be seen in the pressure center of standing balance and swing path, with better postural balance after 5 weeks of training, receiving VR training. For another study in which chronic-phase stroke patients underwent treadmill training in a community-based virtual environment for 30 minutes per day, three times per week, showed significant improvements in limb swing speed, anterior-posterior and overall swing length after 5 weeks of training. The study also revealed that the use of VR technology can significantly improve Berg Balance Scale scores in patients with chronic-onset stroke, improving both static and dynamic balance. Other studies have also demonstrated that appling virtual reality-based training based on conventional balance rehabilitation for 30 minutes per day, 3 times per week for 6 weeks to patients recovering from stroke with balance function disorder, provided visual and auditory feedback, they are capable of shifting the weight of the limb to the left and right side. All these results reveal that patients given VR technology-related treatment can witness a significant boost in balance function and postural control. In summary, virtual reality technology is a means of integrating visual input and movement output, which can be widely used in the recovery of functional impairment after stroke and is effective in improving the balance function and the ability of daily activities of stroke patients. VR balance rehabilitation training, based on conventional rehabilitation therapy, is more vivid and interesting, and is conducive to better overall clinical outcomes."

08:36 EDT Fujifilm Healthcare Americas awarded Pacific Air Force/Navy order - FUJIFILM Healthcare Americas Corporation has been awarded a Pacific Air Force/Navy contract from the U.S. Department of Defense to standardize its digital imaging network's picture archiving and communication systems in U.S. Naval and Air Force medical treatment facilities with the company's Synapse PACS. The award was earned through Fujifilm's 2017 DIN-PACS contract with the Defense Logistics Agency.

08:34 EDT T2 Biosystems announces submission for FDA BDD for T2Biothreat Panel - T2 Biosystems announced that it has submitted an application with the U.S. Food and Drug Administration, FDA, for Breakthrough Device Designation, BDD, for the Company's T2Biothreat Panel. The T2Biothreat Panel is a direct-from-blood test panel designed to run on our commercially available T2Dx Instrument and is designed to simultaneously detect six biothreat pathogens that are listed by the Centers for Disease Control and Prevention, CDC, as Category A and B biothreat agents, including Bacillus anthracis, Francisella tularensis, Burkholderia mallei, Burkholderia pseudomallei, Yersinia pestis and Rickettsia prowazekii. "We are honored to leverage our technology platform to develop products with the potential to protect our nation from the threat of bioterrorism," stated John Sperzel, Chairman and CEO of T2 Biosystems. "We initiated the U.S. clinical trial for the T2Biothreat Panel in December 2021 and we are taking actions to potentially accelerate the commercial availability of our novel T2Biothreat Panel."

08:33 EDT Amwell announces Susan Worthy as Chief Marketing Officer - Amwel announced Susan Worthy has joined the company as Chief Marketing Officer. Susan is a tenured marketing executive with more than 25 years of experience leading marketing for healthcare services and technology companies. In her new role, Susan will be responsible for leading Amwell's overall marketing strategy and will play a pivotal part in building upon the company's market position to drive continued growth, as well as shareholder and customer value. "We are thrilled to have Susan join our executive team. Her impressive background combined with her creativity, data-driven approach and proven track record of working with and leading the marketing strategy for market leading companies, made it clear that she was the right person to further enhance our market differentiation, cross-functional go-to-market strategies and serve as a strategic partner," said Brendan O'Grady, Chief Growth and Commercial Officer, Amwell. "As we continue to navigate through a time of great transformation for Amwell and for our industry, I am confident that Susan will have an immediate impact on our team and our ability to serve current and future customers." Susan joins Amwell from Optum, where she spent the past six years leading marketing teams, driving product value, and establishing thought leadership and market awareness to achieve growth and shareholder value. Prior to Optum, Susan served as a marketing leader for Aetna and Best Doctors as well as several other healthcare companies. Susan has a passion for brand storytelling and is highly regarded for her dynamic leadership and ability to build and motivate results-driven teams.

08:33 EDT Jabil announces next step in manufacturing, supply chain pact with ams OSRAM - Jabil announced the next step in its manufacturing and supply chain collaboration with ams OSRAM, a global leader in optical solutions, with the development of a lateral flow testing platform. The COVID-19 pandemic brought the topic of testing to the forefront, validating the importance of reliable and robust lab-quality testing that can be conducted remotely and with fast turnaround times. With the role of testing only increasing in the future for infectious diseases beyond the current crisis, the teams at ams OSRAM and Jabil saw an opportunity to bring these lateral flow tests into the digital age, leveraging optics and connectivity technologies to simplify patient experience and deliver clear results in approximately 15 minutes.

08:30 EDT Apple: Self service repair available in US, to expand to additional countries - Apple announced Self Service Repair is now available, providing repair manuals and genuine Apple parts and tools through the Apple Self Service Repair Store. Self Service Repair is available in the US and will expand to additional countries - beginning in Europe - later this year. The new online store offers more than 200 individual parts and tools, enabling customers who are experienced with the complexities of repairing electronic devices to complete repairs on the iPhone 12 and iPhone 13 lineups and iPhone SE such as the display, battery, and camera. Later this year the program will also include manuals, parts, and tools to perform repairs on Mac computers with Apple silicon. To start the Self Service Repair process, a customer will first review the repair manual for the product they want to repair by visiting support.apple.com/self-service-repair. Then, they can visit the Apple Self Service Repair Store and order the necessary parts and tools. Every genuine Apple part is designed and engineered for each product, and goes through extensive testing to ensure the highest quality, safety, and reliability. The parts are the same ones - at the same price - as those available to Apple's network of authorized repair providers. For certain repairs, customers will receive a credit when returning a replaced part for recycling.

08:29 EDT Praxis Precision Medicines to host 2022 Epilepsy Day - Praxis Precision Medicines will host its 2022 Epilepsy Day live in New York City and via webcast from 8:30 to 11:30 a.m. ET. Key highlights of the event include: An overview of Praxis' proprietary innovation strategy, driven by its understanding of genetics and translational tools, to rapidly discover and develop targeted CNS drugs, which has led to an epilepsy portfolio representing a multi-billion-dollar market opportunity; Updates from Praxis' three most advanced epilepsy programs, each of which is expected to be clinical stage by year-end 2022: PRAX-222: Investigational New Drug submitted to the U.S. Food and Drug Administration proposing a seamless study design for SCN2A patients with early-onset seizures; PRAX-562: Preliminary 28-day exposure Phase 1 data supports long-term dosing with an unprecedented therapeutic window for sodium channel blockers. A Phase 2 clinical study in cohorts of children with SCN2A epilepsy, SCN8A epilepsy, and Tuberous Sclerosis Complex is expected to initiate in 2H2022 ; PRAX-628: Expected initiation of a Phase 1 study in the fourth quarter of 2022 and a Phase 2 study in focal epilepsy in 2023. A review of the significant progress in Praxis' early-stage epilepsy pipeline, including plans to declare antisense oligonucleotide candidates for PRAX-080 for PCDH19 and PRAX-090 for SYNGAP1 in 2023. A discussion by world-renowned epilepsy experts of the unmet need in clinical management of epilepsy today and perspective on the opportunity for precision-based therapies.

08:27 EDT Cassava says NYT reporter failed to report conflicts, 'misrepresented' company - In a letter that Cassava Sciences sent to the Science Editor of the New York Times that was disclosed in a regulatory filing, the company stated in part: "Regarding The New York Times article, 'Scientists Question Data Behind an Experimental Alzheimer's Drug', by Apoorva Mandavilli (April 18, 2022): we're disappointed the reporter relied almost exclusively on sources known to be critical of Cassava Sciences, failed to report on conflicts of interests and misrepresented our Company. It appears this reporter had a pre-set narrative and wrote an article to fill in the plot. That hardly fits with The New York Times' reputation of producing a solid, fair investigative piece. The reporter states she contacted nine sources. Seven of those had previously made critical, negative statements about Cassava Sciences, all readily accessible by Google or Twitter search. By double-tapping into sources known to be negative, the reporter seems to have exploited a negativity bias to make a pre-determined point. This flies in the face of objectivity... Cassava Sciences competes zealously with large and small biopharmaceutical companies, but we deal with competitors openly and honestly. We do not invent obstacles to hamstring their efforts. Like the New York Times, we observe standards that govern our dealings with critics and colleagues alike. We only wish the New York Times reporter had treated us the same way. From the onset of the short attack against Cassava Sciences I have said that allegations of research misconduct are false. I believe in our science, our people, our clinical programs and our academic collaborator at CUNY, Professor Hoau-Yan Wang. Some of our vocal critics made obscene amounts of money using extreme tactics: filing a Citizen Petition with FDA, reaching out to government agencies and launching a campaign against us. We are disappointed The New York Times reporter failed to see through this agenda. Those who stifle potential new treatments for Alzheimer's are attacking patients, pure and simple. The burden of Alzheimer's is devastating. Patients' lives are at stake, and our drug may help. In the end, proof will be in the clinical data itself. Phase 3 studies will prove or disprove the safety and efficacy of simufilam in Alzheimer's disease. The rest may be noise, competition, profiteering or sour grapes. I had hoped a fair-minded reporter would see and report it as such." Reference Link

08:23 EDT American Resources joins global Rare Earth Industry Association - American Resources Corporation announced that it has joined the global Rare Earth Industry Association, an international non-profit organization representing the global rare earth element industry.

08:19 EDT DraftKings announces Mike Golic Jr. joins, to host new podcast - DraftKings has announced the signing of former Notre Dame Football player and television personality, Mike Golic Jr. In his first project with DraftKings, Golic Jr. will partner with former teammate, Brandon Newman. "GoJo," a new daily podcast scheduled to debut on May 2, will offer a unique perspective on topics across sports and culture. The hour-long video podcast will air five days a week. Monday through Friday, the duo will break down the biggest games of the week while hosting regular guests and larger than life personalities across sports and media. "Mike's addition to the media family is another example of DraftKings partnering with high-profile talent and trusted personalities across sports media," said Stacie McCollum, Vice President of Programming at DraftKings. "Leveraging his strong social currency, he and Brandon will tackle subjects that represent the broader interests and hobbies of today's sports fan."

08:17 EDT Achieve Life announces results from Phase 3 ORCA-2 trial of cytisinicline - Achieve Life Sciences announced positive topline results from the Phase 3 ORCA-2 trial of cytisinicline. ORCA-2 was designed to evaluate the efficacy and safety of 3mg cytisinicline dosed 3 times daily for a period of 6-weeks or 12-weeks compared to placebo in 810 adult smokers. Subjects were monitored for smoking abstinence for 24 weeks post randomization and received standard behavioral support for the duration of the trial. The primary endpoints for ORCA-2 were biochemically verified continuous abstinence measured during the last 4 weeks of treatment. Both the 6- and 12-week cytisinicline treatments demonstrated significantly better quit rates than placebo with odds ratios of 8.0 and 6.3, respectively. Subjects who received 12 weeks of cytisinicline treatment had 6.3 times higher odds, or likelihood, to have quit smoking during the last 4 weeks of treatment compared to subjects who received placebo. The abstinence rate during weeks 9-12 was 32.6% for cytisinicline compared to 7.0% for placebo. Subjects who received 6 weeks of cytisinicline treatment had 8 times higher odds, or likelihood, to have quit smoking during the last 4 weeks of treatment compared to subjects who received placebo. The abstinence rate during weeks 3-6 was 25.3% for cytisinicline compared to 4.4% for placebo. The secondary endpoints measured continuous abstinence after treatment out to 24 weeks. Both the 6- and 12-week secondary endpoints demonstrated significantly better quit rates for cytisinicline treated subjects than placebo. The continuous abstinence rate from week 9 to 24 was 21.1% for the 12-week cytisinicline arm compared to 4.8% for placebo, with an odds ratio of 5.3. The continuous abstinence rate from week 3 to 24 was 8.9% for the 6-week cytisinicline arm compared to 2.6% for placebo, with an odds ratio of 3.7. Cytisinicline was well tolerated with no treatment-related serious adverse events reported. "These strongly positive results are extremely encouraging, and we are thrilled for the successful quitters, whom after decades of smoking and multiple attempts, were finally able to kick the habit thanks to cytisinicline and the ORCA-2 trial," commented John Bencich, CEO of Achieve Life Sciences. "These data confirm that cytisinicline, if approved by the FDA, has the potential to become the first new agent approved in nearly two decades and an important treatment option for smoking cessation, which is much needed given the limitations, particularly the significant side effects associated with existing agents. We would like to thank the investigators, healthcare providers, and subjects whose commitment and efforts to ORCA-2 made this trial a success."

08:16 EDT Magnite launches Deal Discovery interface - Magnite announced the launch of Deal Discovery, a self-service user interface to streamline PMP and Auction Package deal creation for a variety of formats. Using the Deal Discovery tool, buyers can curate open market inventory, request PMP deals in minutes, and surface under-exposed audiences by layering in their first-party data and other campaign parameters. Deal Discovery provides buyers with access to addressability, improved workflow, and greater overall PMP campaign visibility.

08:15 EDT ContraFect announces data presentations on CF-370 - ContraFect Corporation announces presentation data showing DLA CF-370 is highly efficacious in a rabbit pneumonia model of a particularly hard-to-treat, extensively-drug-resistant strain of Pseudomonas aeruginosa, and also has the ability to both avoid antimicrobial resistance and suppress antibiotic resistance to commonly-used antibiotics in vitro. These data were recently presented at the 32nd European Congress of Clinical Microbiology & Infectious Diseases Annual Meeting held from April 23-26, 2022 in Lisbon, Portugal. CF-370 ECCMID 2022 Presentations: The studies discussed below further strengthen the potential for a new treatment paradigm of CF-370 used in addition to antibiotics, to achieve optimal efficacy outcomes for patients. In addition to the efficacy data, multiple serial passage studies highlight the favorable resistance profile of CF-370, including the potential ability to suppress resistance to current standard of care antibiotics. These attributes underpin the potential ability of direct lytic agents to mitigate antimicrobial resistance. Oral Presentation Title: In vivo efficacy of CF-370 alone and in addition to amikacin in the rabbit acute pneumonia model caused by an extensively drug-resistant Pseudomonas aeruginosa, AR-769 In this challenging rabbit model of pulmonary infection, multiple dose regimens of CF-370 administered alone and in addition to amikacin, significantly reduced bacteria counts by ~3.0 log10 cfu/g tissue compared to amikacin alone and by ~4.5 log10 cfu/g tissue compared to vehicle controls. Statistically significant reductions of bacteria counts in secondary organs of interest, the spleen and the kidney, were seen when CF-370 was administered in addition to amikacin compared to the administration of amikacin alone. Poster Presentations: Title: Lysin CF-370 exhibits a low propensity for decreased susceptibility in Gram-negative ESKAPE pathogens Utilizing the standard, rigorous 28-day serial passage method to induce in vitro resistance, CF-370 demonstrated an extremely low propensity for developing decreased susceptibility to the Gram-negative ESKAPE pathogens and Escherichia Coli. CF-370's minimum inhibitory concentration values did not change, except for a 2-fold increase with Enterobacter cloacae compared to MIC increases ranging from 32-fold to 512-fold for levofloxacin and ciprofloxacin. Title: Lysin CF-370 suppresses in vitro resistance in Pseudomonas aeruginosa to meropenem, tobramycin and levofloxacin Using the 28-day serial passage method discussed above, CF-370 further demonstrated the ability to suppress in vitro resistance in P. aeruginosa to current standard of care antibiotics - meropenem, tobramycin and levofloxacin. With the addition of only 1/8x MIC of CF-370, resistance of P. aeruginosa was completely suppressed to both tobramycin and levofloxacin and increased only 2-fold to meropenem, compared to 4-fold, 16-fold and 32-fold MIC changes without CF-370. CF-370 and Amurins ECCMID 2022 Poster Presentation: Title: Direct lytic agents, a novel family of antimicrobial agents, have a low propensity for decreased susceptibility in Gram-negative pathogens associated with airway infection in Cystic Fibrosis Using the 28-day serial passage method discussed above, the Company's DLAs, including CF-370 and the lead molecules from its amurin peptide program, all demonstrated an extremely low propensity for developing decreased susceptibility to Gram-negative pathogens associated with respiratory infections in Cystic Fibrosis patients - P. aeruginosa, Stenotrophomonas maltophilia, and Achromobacter xylosoxidans. All DLAs tested had no change to MIC values compared to MIC increases ranging from 32-fold to 256-fold for levofloxacin and ciprofloxacin. Exebacase ECCMID 2022 Poster Presentations: Title: In vitro activity of exebacase against contemporary beta-haemolytic streptococci recovered from US patients with bloodstream infections Exebacase demonstrated activity against a total of 149 BHS recovered from blood cultures collected as part of the SENTRY antimicrobial surveillance program, representing 5.2% of US BSI in the program. Exebacase MIC values ranged from 0.5-4.0 mg/L against Streptococcus agalactiae, Streptococcus pyogenes, and Streptococcus dysgalactiae, warranting further study of the potential for exebacase to treat BSI caused by BHS. The studies below describe the optimization and expanded use of the exebacase MIC method in order to test additional target pathogens, such as beta-hemolytic streptococci, that have not been studied in clinical trials, but are relevant to bloodstream infections, including right-sided endocarditis. These studies are being performed in late-stage development to evaluate in vitro activity of exebacase against contemporary target pathogens relevant to the patient population under investigation in Phase 3 and for consideration of potential inclusion in product labeling. Title: Evaluation of the broth microdilution MIC method for exebacase against 100 beta-haemolytic streptococci Title: Assessment of exebacase MIC reproducibility: Thirty S. aureus isolates tested at three sites using three different commercial media lots

08:12 EDT AcelRx to host KOL webinar on Niyad nafamostat program - AcelRx Pharmaceuticals announced that it will host a Key Opinion Leader webinar on Wednesday, May 4, 2022 at 1:00 pm Eastern Daylight Time. The webinar will discuss its recently acquired late-stage product candidate, Niyad, a lyophilized form of nafamostat, a regional dialysis anticoagulant already approved in Japan and Korea. In the U.S., the Food and Drug Administration has granted Niyad Breakthrough Device Designation status for injection into the extracorporeal circuit, the most commonly known being dialysis machines, to prevent clotting and ensure effective treatment is provided to the patient. The webinar will feature presentations from two internationally renowned acute kidney injury experts, Stuart Goldstein, MD, from Cincinnati Children's Hospital, and Lakhmir Chawla, MD, former Chief of the Division of Intensive Care Medicine at the Washington D.C. Veterans Affairs Medical Center, who will discuss the unmet medical need for anticoagulation of the extracorporeal circuit. There are currently no FDA-approved regional anticoagulants for use in this setting. Niyad is being regulated as a device by the FDA and has been approved and used in Japan and Korea for several decades. Nafamostat is a broad-spectrum, synthetic serine protease inhibitor, and, in addition to anticoagulant properties, it also has anti-inflammatory properties and potential anti-viral activities. LTX-608 is a separate product candidate in the nafamostat program, with potential development by AcelRx for multiple conditions - including as a treatment for disseminated intravascular coagulation and as an anti-viral treatment for COVID-19 and other indications.

08:10 EDT Telos announces Xacta 360 Lite for CMMC VMI offering - Telos Corporation announced its new Xacta 360 Lite for Cybersecurity Maturity Model Certification Virtual Machine Infrastructure offering to automate and streamline the activities required for CMMC assessment. CMMC is a unifying standard developed by the U.S. Department of Defense to ensure that members of the defense supply chain apply sound cybersecurity and risk management practices in order to protect federal contract and controlled unclassified information. There are approximately 300,000 federal contractors that need to adhere to CMMC. In addition to traditional federal contractors, higher education and other organizations conducting research on behalf of the government will also need to comply with CMMC. Available on the Azure Marketplace, Xacta 360 Lite CMMC VMI helps users quickly and easily navigate the CMMC assessment process from end-to-end. Developed to support contractors and vendors that require self-attestation or need to prepare for CMMC certification and assessment by a CMMC Third Party Assessment Organization, the Xacta 360 Lite CMMC VMI is a turnkey solution that is easy to set up and navigate. Customers can use up to five CMMC licenses for unique CMMC efforts, in addition to gaining access to basic training videos to help ease concerns and streamline the assessment process.

08:09 EDT AMSC announces $24M of new energy power systems orders - AMSC announced $24M of new energy power systems orders. This includes orders for reactive compensation, enclosed capacitor banks, harmonic filters, voltage controllers, rectifiers and transformers. "As the world gears up for decarbonization to slow down climate change and create a path for a more sustainable world, so does the increased demand for renewable energy, semiconductors, and key materials for the new green economy, such as metals, mining, and chemicals," said Daniel McGahn, Chairman, President and CEO, AMSC. "We are experiencing a great start to fiscal 2022 with strong bookings of new energy power systems." AMSC's new energy power systems solutions include D-VAR and VVO offerings as well as NEPSI and Neeltran businesses. Along with Neeltran, AMSC offers power conversion products. These products include transformers and rectifiers. Additionally, the systems help utilities manage their power quality concerns and expand grid capacity for renewable distributed generation.

08:07 EDT Allogene Therapeutics receives FDA ODD for ALLO-605 - Allogene Therapeutics announced that the U.S. Food and Drug Administration, FDA, has granted orphan-drug designation, ODD, to ALLO-605, the company's next-generation AlloCAR T product candidate targeting BCMA for the treatment of multiple myeloma. ALLO-605 is the Company's first TurboCAR product candidate. The FDA granted Fast Track designation to ALLO-605 in Q2 2021 based on the potential for the product candidate to address an unmet need for patients who have failed other standard multiple myeloma therapies. The Phase 1 study evaluating ALLO-605 is ongoing. "Orphan-drug designation marks an important step towards developing our anti-BCMA portfolio for patients with multiple myeloma and making allogeneic CAR T products readily available for patients," said Rafael Amado, M.D., Executive Vice President of Research and Development and Chief Medical Officer. "We look forward to providing an update on our BCMA clinical assets by the end of the year with an eye toward prioritizing a strategy for the next stage of development."

08:06 EDT Draganfly says Perry County Schools purchases Vital Intelligence Smart Kiosks - Draganfly announced that the company's Vital Intelligence Smart Vital Kiosks have been implemented in Perry County, Alabama by the Perry County School District. Perry County Schools is a public school district serving students from pre-kindergarten to grade 12. Powered by Draganfly's Vital Intelligence platform, the Smart Vital Kiosks can screen, with voluntary consent, temperature, blood pressure, heart rate, respiratory rate and oxygen saturation in seconds. "Every student has the right to a safe learning environment. We are incredibly grateful for the opportunity to work with Perry County Schools to uphold that commitment. Our Vital Intelligence platform adds another layer of health security, which will help provide peace of mind inside and outside of the classroom," said Cameron Chell, CEO of Draganfly.

08:06 EDT Hertz appoints Ned Ryan as Chief Product Development Officer - Hertz announced that Ned Ryan will join the company as Chief Product Development Officer, effective May 9. Ryan launched Breeze in 2013, the first flexible rideshare financing platform, which was purchased by Ford in 2016. He also founded Canvas, a vehicle subscription service that was purchased by Fair.com at the end of 2019. Ryan most recently served in a senior capacity at Ford.

08:04 EDT Abbott, CamDiab and Ypsomed to develop automated insulin delivery system - Abbott, CamDiab and Ypsomed are partnering to develop and commercialize an integrated automated insulin delivery system to help lessen the burden of round-the-clock diabetes management for people with diabetes. The initial focus of the partnership will be in European countries. The new integrated AID system is being designed to connect Abbott's FreeStyle Libre 3 continuous glucose monitoring sensor to CamDiab's CamAPS FX mobile app, which connects with Ypsomed's mylife YpsoPump - creating a process to deliver insulin based on real-time glucose data. The connected, smart wearable solution is designed to continuously monitor a person's glucose levels and automatically adjust and deliver the right amount of insulin at the right time, removing the guesswork of insulin dosing. The companies intend to complete development by end of 2022 with commercial availability expected thereafter.

08:02 EDT Caladrius, Cend Therapeutics to merge in all-stock transaction - Caladrius Biosciences and Cend Therapeutics announced that the companies have entered into a definitive merger agreement under which Cend will merge with a wholly owned subsidiary of Caladrius in an all-stock approximate "merger of equals" transaction unanimously approved by the Boards of Directors of each company. Following closing, the combined company will be renamed Lisata Therapeutics and will trade on the Nasdaq under the ticker symbol "LSTA". The merger is currently expected to close in the third quarter of 2022 subject to the approval of Caladrius and Cend stockholders as well as the satisfaction of certain other customary closing conditions and applicable approvals. Following the closing of the merger, Lisata is expected to advance CEND-1 as its lead product candidate in a variety of difficult to treat solid tumor applications, including pancreatic ductal adenocarcinoma, where the product is being evaluated in ongoing Phase 1 and Phase 2 clinical studies with Cend and its partner in China, Qilu Pharmaceutical. CEND-1 is a proprietary cyclic peptide which undergoes protease mediated cleavage in the tumor microenvironment producing a C-end Rule or "CendR" peptide that potentiates transport across the tumor stroma and improves delivery of anticancer drugs to the tumor. Additional Phase 1b/2 PDAC clinical data is expected as early as 2023. Lisata also plans to initiate an additional trial in PDAC in combination with immunotherapy as well as a trial or trials exploring applications of CEND-1 in other difficult to treat solid tumors, such as hepatocellular, gastric and breast cancers along with additional therapeutic combinations. We see CEND-1's advancement as supported by compelling Phase 1b data previously presented at the 2020 European Society for Molecular Oncology, which not only demonstrated favorable safety and tolerability, but importantly, the potential for marked improvement in treatment effectiveness in combination with standard of care drugs for PDAC.1 With its unique tumor-targeted, tissue penetrating technology, we believe that the CendR Platform holds the potential to enable more effective solid tumor treatment for a range of emerging treatment modalities, including RNA-based drugs. We believe that this could provide Lisata with additional partnering and product opportunities to benefit cancer patients and Lisata shareholders. Under the terms of the definitive merger agreement, David J. Mazzo, Ph.D., current President and CEO of Caladrius will be the Chief Executive Officer of Lisata, David Slack, current President and CEO of Cend, will be Lisata's President and Chief Business Officer, and Kristen K. Buck, MD, current Executive Vice President of R&D and Chief Medical Officer, will continue in those roles with Lisata. Upon closing, shareholders of Cend will receive approximately 60.5 million shares of Caladrius common stock, subject to certain closing conditions, resulting in the shareholders of each company owning approximately 50% of the combined company. The transaction values each company at $90 million, which for Caladrius represents a 136% premium to its market cap as of the market close on April 26, 2022. At the effective time of the merger, the Board of Directors of Lisata is expected to comprise four directors designated by Caladrius and four directors designated by Cend, with the possibility of one additional independent director, whose appointment will be mutually agreed upon by both Caladrius and Cend.

07:55 EDT Achieve Life Sciences trading halted, news pending

07:46 EDT CGI Inc. enters pact to acquire Harwell Management, terms not disclosed - CGI announced that it has entered into an agreement for the acquisition, through its subsidiary CGI France SAS, of all of the shares of Harwell Management holding and their subsidiaries. Harwell Management is a management consulting firm specializing in the financial services industry and operating mainly within the French market. Founded in 2009, Harwell Management has approximately 150 consultants who support large financial institutions, including banks and insurers, in defining and executing purpose-driven strategies, adhering to ever-evolving regulations, building competitive advantage, and accelerating sustainable value and long-term growth. The signing of the share purchase agreement and completion of the acquisition would only take place after completion of the information and consultation procedures of the relevant employee representative bodies of Harwell Management and CGI France.

07:44 EDT Alterity Therapeutics' Phase 2 trial of MSA candidate authorized in the U.K - Alterity Therapeutics announced that the U.K.'s Medicines & Healthcare products Regulatory Agency - MHRA - has accepted Alterity's clinical trial authorisation request to conduct its Phase 2 clinical trial for ATH434 in Multiple System Atrophy - MSA -, a rare and highly debilitating Parkinsonian disorder. The Phase 2 clinical trial is a placebo-controlled investigation of ATH434 in patients with early-stage MSA. The study will explore the effect of ATH434 treatment on imaging and protein biomarkers such as aggregating alpha-synuclein and excess iron, which are important contributors to MSA pathology. Patients will receive treatment for 12 months which will provide an opportunity to detect changes in efficacy endpoints to optimize design of a definitive Phase 3 study.

07:43 EDT Lilium progresses toward EASA DOA with successful second audit - Lilium N.V. announced that it has successfully completed the second Design Organization Approval, DOA, audit by the European Union Aviation Safety Agency, EASA. DOA is a fundamental requirement for all commercial aircraft manufacturers and enables achievement of type certification of an aircraft. "The completion of the audit demonstrates that Lilium is following the rigorous design processes agreed with EASA and represents a further milestone on Lilium's path to type certification and subsequent serial production of its conforming aircraft," the company said. Two further EASA DOA audits will be required for Lilium to receive the organizational approval, which complements the certification and development program. The fourth and final EASA DOA audit and granting of EASA DOA is anticipated to coincide with type certification of the Lilium Jet.

07:41 EDT Solid Biosciences expects cash to fund operations into 2Q24 - Solid had $180.1 million in cash, cash equivalents and available-for-sale securities as of March 31, 2022. The company expects that its cash, cash equivalents and available-for-sale securities will enable Solid to fund its operations and capital expenditures into the second quarter of 2024.

07:40 EDT Comcast, Charter form joint venture to develop streaming platform - Charter (CHTR) and Comcast (CMCSA) announced that the two companies have formed a 50/50 joint venture to develop and offer a streaming platform on a variety of branded 4K streaming devices and smart TVs, providing consumers with a user experience and navigation, all the apps, and more choice in the streaming marketplace. The joint venture will offer app developers, streamers, retailers, operators, and hardware manufacturers the opportunity to reach customers in major markets across the country with the platform. Comcast will license Flex, its aggregated streaming platform and hardware to the joint venture, contribute the retail business for XClass TVs and also will contribute Xumo, a streaming service it acquired in 2020. Charter will make an initial contribution of $900M, funded over multiple years. The XClass TVs will be available through national retail partners and potentially direct from Comcast and Charter to provide more customer choice. The closing of the joint venture is subject to customary closing conditions. This joint venture does not involve the broadband or cable video businesses of either Comcast or Charter which will remain independent.

07:39 EDT Boeing continues to see passenger traffic returning to 2019 levels in 2023-2024 - Sees return to long-term trend "a few years thereafter." Notes that February cargo traffic was roughly 12% above 2019 levels. Says war in Ukraine creating near-term challenges. Sees first delivery of the 777-9 in 2025. Comments taken from Q1 earnings conference call presentation slides.

07:36 EDT Boeing reports Q1 commercial airplane deliveries of 95 vs. 77 a year ago - Boeing has nearly completed the global safe return to service of the 737 MAX and the fleet has flown more than one million total flight hours since late 2020. The 737 production rate continues to increase and is expected to increase to 31 airplanes per month during the second quarter. On the 787, the company has submitted the certification plan to the FAA. Rework has been completed on the initial airplanes and the company continues to work closely with the FAA on timing of resuming deliveries. The program is producing at a very low rate and will continue to do so until deliveries resume, with an expected gradual return to five per month over time. The company continues to anticipate 787 abnormal costs of approximately $2 billion, with most being incurred by the end of 2023, including $312 million recorded in the quarter. During the quarter, the company launched the 777-8 Freighter with an order from Qatar Airways. Delivery of the first 777-9 airplane is now expected in 2025, which reflects an updated assessment of the time required to meet certification requirements. To minimize inventory and the number of airplanes requiring change incorporation, the 777-9 production rate ramp is being adjusted, including a temporary pause through 2023. This will result in approximately $1.5 billion of abnormal costs beginning in the second quarter of this year and continuing until 777-9 production resumes. The 777 program is also leveraging the adjustment to the 777-9 production rate ramp to add 777 Freighter capacity starting in late 2023. Commercial Airplanes delivered 95 airplanes during the quarter and backlog included nearly 4,200 airplanes valued at $291 billion.

07:34 EDT Boeing CEO says 'on track to generate positive cash flow for 2022' - "While the first quarter of 2022 brought new challenges for our world, industry and business, I am proud of our team and the steady progress we're making toward our key commitments," said Dave Calhoun, Boeing president and CEO. "We increased 737 MAX production and deliveries and made important progress on the 787 by submitting our certification plan to the FAA. Despite the pressures on our defense and commercial development programs, we remain on track to generate positive cash flow for 2022, and we're focused on our performance as we work through certification requirements and mature several key programs to production. Leading with safety and quality, we're taking the right actions to drive stability throughout our operations, deliver on our commitments to customers and position Boeing for a sustainable future."

07:33 EDT Caladrius trading halted, news pending

07:32 EDT Boeing reports Q1 operating cash flow ($3.2B) - Continues to expect positive cash flow for 2022.

07:32 EDT WPP: Sees LFL revenue less pass-through costs growth now expected to be 5.5-6.5% - $1.8B in net new business won, including Mars, JDE Peet's, Sky; Launch of Everymile, our commerce-as-a-service proposition; acquisition of Village Marketing; merger of Mediacom and Essence, and creation of GroupM Nexus. GBP 362 million of share buybacks in Q1. 2022 guidance raised: LFL revenue less pass-through costs growth now expected to be 5.5-6.5%, up from around 5% "The year has started very well with continued momentum from 2021 resulting in strong growth across all businesses and regions. Demand is strong for our services, particularly in digital media, ecommerce, data and marketing technology. "The war in Ukraine has created an appalling humanitarian crisis. We continue to support our people in Ukraine, many of whom are now displaced, with financial and practical assistance. Our partnership with the UNHCR on their emergency fundraising appeal has generated $150 million to date, including over $1.3 million from our employee match-funding programme. On 4 March, we announced that we would exit the Russian market, and we have now reached agreement to divest our businesses there.

07:30 EDT NeoGenomics says 'on track to overcome' current challenges - "Our Board of Directors is actively searching for an outstanding leader to serve as our next CEO. In the meantime, our new Clinical Services Division President, Dr. David Sholehvar, and Chief Scientific Officer, Dr. Shashi Kulkarni, bring extensive operating experience and expertise that will enable us to accelerate our efforts to improve operating performance and reinvigorate growth. With an effective interim management structure and team in place and the CEO search well underway, we are confident that we are on track to overcome the current challenges facing our business."

07:26 EDT Auddia announces music distribution, discovery program Discovr - Auddia announced its new music distribution and discovery program, Discovr. Independent artists selected for faidr's Discovr music program will have their songs added to 4500+ live and local radio station playlists by July 1, 2022. Participating artists and radio station programming directors will get access to listening data and be paid for every track play at the standard SoundExchange rate.

07:23 EDT Credit Suisse CFO David Mathers to seek 'alternative opportunities' - Credit Suisse Group announces a series of appointments to its Executive Board and management changes: David Mathers, who has served as CFO since 2010 and as CEO of Credit Suisse International since 2016, has indicated his wish to seek alternative opportunities outside of Credit Suisse. David has agreed to continue his responsibilities until suitable successors for both of his roles have been found, ensuring an orderly transition. Credit Suisse has launched an internal and external search, a process in which David will be involved, to find the optimal candidates for the two roles. Francesca McDonagh will take over by October 1, 2022, as CEO of the EMEA region from Francesco De Ferrari, CEO of the Wealth Management division, who has held this position on an ad interim basis since January 2022. Helman Sitohang has announced his intention to step down from his current role on June 1, 2022. Edwin Low, who has been with the bank since 1996, will replace Helman on the Executive Board and report directly to Group CEO Thomas Gottstein. Markus Diethelm joins on July 1, 2022, as General Counsel, succeeding Romeo Cerutti, who will retire after more than 10 years in the position.

07:22 EDT Northland Power launches refreshed brand - Northland Power announced the launch of a refreshed brand as part of its new global brand strategy. Developed to reinforce its vision for building a sustainable and carbon-neutral world, the refresh is designed to create visual impact in an evolving digital era, drive consistency across borders and strengthen recall between Northland's work, projects and assets. Since its inception in 1987, Northland has grown into a global player with offices in eight countries across four continents. It was the first Canadian independent power producer to expand globally into offshore wind. With a global diversified portfolio of power infrastructure assets and a significant development pipeline, Northland is strategically positioned to support the global decarbonization efforts to foster a carbon-neutral future, while continuing to deliver strong returns to its investors. Key changes to the visual identity as part of the refresh include: Updated logo design - Rooted in Northland's brand story, the new logo combines the Yin & Yang symbol signifying balance through carbon-neutrality and the infinity symbol represented by renewable power, creating a visual mark that evokes constant movement. Bolder greens and welcoming blues - With the green palette symbolizing the earth, and the blue palette symbolizing wind and water, these primary colours serve as a constant visual reminder of what drives Northland as an organization - to power the planet. Modernized tagline - "Intelligent Energy. Greener Planet" consolidates Northland's vision into simple terms, echoing the fast-paced, modern world of today. These words illustrate the organization's core vision that has been in place since the very beginning. Converting all digital and online properties will be Northland's main priority for the remainder of the year, followed by updated print materials, signage, and assets.

07:20 EDT MAG Silver reports Q1 production from Juanicipio - MAG Silver reported Q1 production of underground development and stope material from the Juanicipio Project - 56% / 44% Fresnillo and MAG Silver, respectively -. 145,484 tons of mineralized material were processed during Q1 vs. 36,395 tons in previous year quarter, at an average head grade of 597 silver grams per ton or 17.4 silver ounces/ton vs. 458 g/t or 13.4 silver ounces/ton a year ago. Total Juanicipio production for the quarter based on provisional estimates before offtake agreement adjustments totaled 2.4M silver ounces and 5,837 gold ounces vs. 462,321 silver ounces and 697 gold ounces a year ago. MAG's attributable 44% production interest for the quarter totaled 1,056,000 silver ounces and 2,568 gold ounces vs. 203,421 silver ounces and 307 gold ounces in the year ago quarter. Construction of the Juanicipio plant was delivered by Fresnillo on schedule during 4Q21. According to Fresnillo, the power tie-in remains on track for mid-2022, with the expectation to ramp up the Juanicipio processing plant to 85-90% of capacity by year end.

07:18 EDT First Wave BioPharma forms clinical steering committee - First Wave BioPharma announced the formation of a clinical steering committee focused on advancing the Company's inflammatory bowel disease product portfolio. The four-member steering committee will provide management with strategic guidance and support during the execution of the FW-UP Phase 2 trial as well as the advancement of clinical programs for FW-UC and FW-CD. The committee members include Brian Feagan; Stephen Hanauer, and Clifford Joseph Barborka; Giovanni Monteleone; and Julian Panes. "Our inflammatory bowel disease product portfolio, led by FW-UP, is a significant near-term and longer-range growth driver for First Wave BioPharma and was a key factor in our decision to acquire First Wave Bio. Given this importance to the company, we are very excited to announce the formation of a clinical steering committee comprised of world-renowned experts in IBD," stated James Sapirstein, President and CEO of First Wave BioPharma. "Each committee member brings extensive expertise as researchers and clinicians in the treatment of gastrointestinal and inflammatory bowel diseases, including ulcerative colitis and Crohn's disease. We expect to benefit immediately from their collective experience as we accelerate our FW-UP program and look to initiate clinical trials of FW-UC and FW-CD."

07:15 EDT Global-e Online and Klarna expand global partnership to Canada - Global-e announced its expanded partnership with Klarna, a global retail bank, payments, and shopping service. Through this partnership, merchants selling to Canada via Global-e's cross-border e-commerce platform, including notable brands such as Reformation, SKIMS, Fenty Beauty, Rimowa, Versace, Marc Jacobs, and Marks & Spencer, can now offer consumers Klarna's flexible payment options. Klarna's suite of alternative payment solutions is now available to retailers selling in Canada via Global-e's cross-border e-commerce platform.

07:13 EDT Caladrius, Cend Therapeutics to merge in all-stock transaction - Caladrius Biosciences, and Cend Therapeutics announced that the companies have entered into a definitive merger agreement under which Cend will merge with a wholly owned subsidiary of Caladrius in an all-stock approximate "merger of equals" transaction unanimously approved by the Boards of Directors of each company. Following closing, the combined company will be renamed Lisata Therapeutics, and will trade on the Nasdaq under the ticker symbol "LSTA". The merger is currently expected to close in the third quarter of 2022 subject to the approval of Caladrius and Cend stockholders as well as the satisfaction of certain other customary closing conditions and applicable approvals. Following the closing of the merger, Lisata is expected to advance CEND-1 as its lead product candidate in a variety of difficult to treat solid tumor applications, including pancreatic ductal adenocarcinoma, where the product is being evaluated in ongoing Phase 1 and Phase 2 clinical studies with Cend and its partner in China, Qilu Pharmaceutical. CEND-1 is a proprietary cyclic peptide which undergoes protease mediated cleavage in the tumor microenvironment producing a C-end Rule or "CendR" peptide that potentiates transport across the tumor stroma and improves delivery of anticancer drugs to the tumor. Additional Phase 1b/2 PDAC clinical data is expected as early as 2023. Lisata also plans to initiate an additional trial in PDAC in combination with immunotherapy as well as a trial or trials exploring applications of CEND-1 in other difficult to treat solid tumors, such as hepatocellular, gastric and breast cancers along with additional therapeutic combinations. We see CEND-1's advancement as supported by compelling Phase 1b data previously presented at the 2020 European Society for Molecular Oncology, which not only demonstrated favorable safety and tolerability, but importantly, the potential for marked improvement in treatment effectiveness in combination with standard of care drugs for PDAC. With its unique tumor-targeted, tissue penetrating technology, we believe that the CendR Platform holds the potential to enable more effective solid tumor treatment for a range of emerging treatment modalities, including RNA-based drugs. We believe that this could provide Lisata with additional partnering and product opportunities to benefit cancer patients and Lisata shareholders. Under the terms of the definitive merger agreement, David J. Mazzo, Ph.D., current President and CEO of Caladrius will be the Chief Executive Officer of Lisata, David Slack, current President and CEO of Cend, will be Lisata's President and Chief Business Officer, and Kristen K. Buck, MD, current Executive Vice President of R&D and Chief Medical Officer, will continue in those roles with Lisata. Upon closing, shareholders of Cend will receive approximately 60.5 million shares of Caladrius common stock, subject to certain closing conditions, resulting in the shareholders of each company owning approximately 50% of the combined company. The transaction values each company at $90 million, which for Caladrius represents a 136% premium to its market cap as of the market close on April 26, 2022. At the effective time of the merger, the Board of Directors of Lisata is expected to comprise four directors designated by Caladrius and four directors designated by Cend, with the possibility of one additional independent director, whose appointment will be mutually agreed upon by both Caladrius and Cend.

07:11 EDT Societal CDMO secures manufacturing, packaging task order award from NCI - Societal CDMO announced that it has been awarded a new manufacturing and packaging task order agreement by the National Cancer Institute's Division of Cancer Treatment and Diagnosis. The new contract is an individual task order of more than $400,000 for the manufacture and packaging of ammonium tetrathiomolibdate capsules to support clinical development of the compound. Under terms of the new task order award, Societal CDMO will develop and provide DCTD with a scalable manufacturing and packaging process for cGMP production of 100 mg ATTM capsules. This work will include production and packaging of an initial engineering batch of ATTM, followed by production and packaging of a larger cGMP batch of the capsules including a 36-month shelf-life stability study. ATTM acts to interfere with intestinal uptake of copper when administered with meals and binds plasma copper when taken between meals. Based on this mechanism of action, the compound is believed to have the potential to enhance the activity of platinum-based antitumor agents.

07:10 EDT Enthusiast Gaming surpasses 1B monthly views in the U.S. - Enthusiast Gaming announced that its digital media property surpassed one billion Total Views per month in the United States, based on recent digital media ratings from Comscore, Total Views to the Company's property in the U.S reached 1.1 billion in March 2022, representing a 44% increase versus March 2021. The growth aligned with the highly-anticipated release of Elden Ring by Bandai Namco Entertainment, with a high volume of reviews, guides, forums, and videos delivered across the Company's platform of video game fan communities.

07:07 EDT Zentalis announces $25M equity investment from Pfizer - Zentalis Pharmaceuticals, Inc. (ZNTL) announced that it has agreed to sell 953,834 of its common shares at a price of $26.21 per share to Pfizer (PFE) for gross proceeds of $25.0 million (the "Transaction"). The common shares were offered and sold to Pfizer in a registered direct offering conducted without an underwriter or placement agent. The offering is expected to close on or about April 29, 2022, subject to customary closing conditions. Zentalis intends to use the net proceeds of the offering to help fund ongoing and planned clinical trials, including studies of ZN-c3, its Wee1 inhibitor, and ZN-d5, its BCL-2 inhibitor, and for working capital and general corporate purposes. With prioritization of the clinical development of ZN-c3 and ZN-d5, budget reallocation and Pfizer's investment, the Company extends current cash runway into Q1 2024. Pfizer also expects to leverage its global development capabilities and expertise to enhance Zentalis' clinical development program. The parties have entered into an agreement to collaborate to advance the clinical development of ZN-c3, a selective Wee1 inhibitor designed to induce synthetic lethality in cancer cells. Zentalis will maintain full economic ownership and control of ZN-c3 and the rest of its pipeline. In addition, Adam Schayowitz, Ph.D., MBA, Vice President & Medicine Team Group Lead for Breast Cancer, Colorectal Cancer and Melanoma, Pfizer, will join Zentalis' Scientific Advisory Board. Dr. Schayowitz will work closely with Zentalis' senior management team to provide input on the Company's clinical strategy.

07:05 EDT Kraft Heinz sees FY22 organic net sales mid-single-digit percentage increase - The Company continues to expect strong financial performance in 2022. The Company is raising expectations for 2022 Organic Net Sales to a mid-single-digit percentage increase versus the prior year period, reflecting strong performance to date, ongoing business momentum, and additional pricing actions to mitigate ongoing inflation. The Company continues to expect Adjusted EBITDA to be in the range of $5.8 billion to $6.0 billion with a 48 percent to 52 percent first half to second half split. This reflects a 53rd week in 2022, the impact of divestitures versus the prior year, strong Organic Net Sales as well as the Company's ongoing efforts to manage inflationary pressures, including unlocking gross efficiencies, as it continues to invest in long-term growth.

07:03 EDT Harley-Davidson reaffirms FY22 guidance - For the full year 2022, the company reaffirms its initial guidance and continues to expect: HDMC revenue growth of 5 to 10%; HDMC operating income margin of 11 to 12%; HDFS operating income to decline by 20 to 25%; Capital investments of $190 million to $220 million. The outlook assumes that logistics and manufacturing moderately improve in the back-half the year as we get beyond the peak levels of inflation experienced in 2021 and the semi-conductor supply stabilizes; the company now expects raw material inflation to continue through the balance of the fiscal year. The company's cash allocation priorities are to fund growth through The Hardwire initiatives, pay dividends, and execute discretionary share repurchases.

07:02 EDT Aslan Pharmaceuticals announces upcoming milestones - Initiation of Phase 2 study of farudodstat, also known as ASLAN003, in inflammatory bowel disease is planned for the first half of 2022. New data on biomarkers and patient reported outcome measures from the Phase 1b proof-of-concept study of eblasakimab expected in the second half of 2022. Topline data from the Phase 2b TREK-AD study of eblasakimab is expected in the first half of 2023.

06:58 EDT T-Mobile reports Q1 postpaid net account additions 348K - Reports Q1: Postpaid net customer additions of 1.3M; Postpaid phone net customer additions of 589K; High Speed Internet net customer additions of 338 thousand, "best in industry and record high".

06:53 EDT Kimco Realty raises quarterly cash dividend 5.3% to 20c, declares two dividends - Kimco Realty declared a quarterly cash dividend of 20c per common share, representing a 5.3% increase from the prior quarterly dividend. The quarterly cash dividend on common shares is payable on June 23 to shareholders of record on June 9. The company also declared a quarterly dividend with respect to shares of the company's 5.125% Class L and 5.25% Class M cumulative redeemable preferred stock. Dividends on the shares of preferred stock will be paid on July 15 to shareholders of record on July 1.

06:51 EDT Pfizer, Biohaven Pharmaceutical: EC grants marketing approval for VYDURA - Pfizer (PFE) and Biohaven Pharmaceutical (BHVN) announced that the European Commission has granted marketing authorization for VYDURA, a calcitonin gene-related peptide receptor antagonist for both the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine in adults who have at least four migraine attacks per month. VYDURA, an orally disintegrating tablet, is the first medicine approved for both acute and prophylactic treatment of migraine in the European Union.

06:47 EDT Gorman-Rupp to acquire Fill-Rite for $525M - The Gorman-Rupp Company announced that it has entered into a definitive agreement to acquire the assets of Fill-Rite and Sotera, a division of the Tuthill Corporation, for $525M. When adjusted for approximately $80M in expected tax benefits, the net transaction value is approximately $445M. Gorman-Rupp expects to fund the transaction with cash on-hand and new debt. Subject to customary closing conditions and necessary regulatory approvals, the transaction is expected to close in the second quarter of 2022. With facilities in Fort Wayne, Indiana and Lenexa, Kansas, the Fill-Rite and Sotera brands carry strong legacies associated with superior products, and hold leadership positions in attractive niche pump markets. Fill-Rite provides rugged, high performance liquid transfer pumps as well as a comprehensive line of mechanical and digital meters, precision weights and measures certified meters, hand pumps, hoses, nozzles and accessories. For the 12 months ended March 31, 2022, Fill-Rite generated revenue of approximately $140M and adjusted EBITDA of approximately $34.5M, representing an adjusted EBITDA margin of 25%. The transaction is not expected to impact Gorman-Rupp's dividend policy, including maintaining its historic record of annual dividend increases.

06:43 EDT Novartis reports RATIONALE 306 trial met primary endpoint at interim analysis - Novartis (NVS) announced positive topline results from an interim analysis of the Phase III RATIONALE 306 study, which showed anti-PD-1 immune checkpoint inhibitor tislelizumab plus chemotherapy significantly improved overall survival, or OS, compared to chemotherapy in patients with previously untreated unresectable, locally advanced, recurrent or metastatic esophageal squamous cell carcinoma, or ESCC, regardless of PD-L1 expression. Novartis intends to submit these data to regulatory authorities, and will collaborate with BeiGene (BGNE) to present them at an upcoming medical meeting. Approximately 649 study participants were randomized 1:1 to receive either tislelizumab plus chemotherapy or chemotherapy alone. The primary endpoint is OS. Secondary endpoints include progression-free survival, objective response rate, duration of response, health-related quality of life measures and safety. Tislelizumab is currently under review by the US Food and Drug Administration and the European Medicines Agency for advanced or metastatic ESCC after prior chemotherapy. The EMA is also reviewing tislelizumab for advanced or metastatic non-small cell lung cancer, or NSCLC, after prior chemotherapy, and in combination with chemotherapy for previously untreated advanced or metastatic NSCLC.

06:41 EDT GlaxoSmithKline CEO says delivered 'strong' Q1 results - Emma Walmsley, CEO, GSK: "We have delivered strong first quarter results in this landmark year for GSK, as we separate Consumer Healthcare and start a new period of sustained growth. Our results reflect further good momentum across specialty medicines and vaccines, including the return to strong sales growth for Shingrix and continuing pipeline progress. We also continue to see very good momentum in Consumer Healthcare, demonstrating strong potential of this business ahead of its proposed demerger in July, to become Haleon."

06:38 EDT Ameris Bancorp 'well positioned' for rising rate environment - Management is focused on long-term growth in TBV, the company said in slides being presented on its Q1 earnings conference call.

06:38 EDT Acutus Medical refinancing existing debt, selling left-heart access portfolio - Acutus Medical (AFIB) announced a commitment letter from Deerfield Management to refinance its existing debt with a new longer-term credit facility, and in conjunction with the refinancing, a definitive agreement to sell the company's left-heart access portfolio to Medtronic (MDT). The combination of these two transactions, taken together with the company's recently completed restructuring, aim to result in a comprehensive recapitalization of the business to fund the company's strategic growth priorities. Acutus has signed a commitment letter to refinance its existing debt facility. The existing debt facility, which has a maturity date of May 20, 2024, will be replaced with a new debt facility in conjunction with the left-heart access portfolio sale. The new debt facility with Deerfield will include $35M in aggregate principal with a maturity date five-years from the closing of the loan, as well as amortization payments becoming due 36, 48 and 60 months following the closing of the loan. Acutus expects to issue warrants to purchase our common stock to Deerfield in connection with the refinancing. Medtronic will make an upfront cash payment to Acutus of $50M upon the initial closing of the transaction, as well as contingent consideration payments over time based on the achievement of certain milestones and future sales.

06:33 EDT Credit Suisse expects 2022 to be a 'transition' year - The company said, "As previously highlighted at our Investor Day on November 4, 2021, the year 2022 will be one of transition for Credit Suisse. The benefits from the strategic capital reallocation towards our core businesses and the structural cost savings from the reorganization measures that we are currently implementing should largely materialize from 2023 onwards. In this respect, we are focused on disciplined execution of our strategy with a clear focus on strengthening and simplifying our integrated model and investing in sustainable growth, while placing risk management at the very core of the bank."

06:31 EDT Credit Suisse: Revenues will be adversely impacted by reduction in risk appetite - The company said, "The combination of the current geopolitical situation following Russia's invasion of Ukraine and the significant monetary tightening initiated by several of the major central banks in response to inflation concerns have resulted in heightened volatility and client risk aversion so far this year. While the Swiss Bank delivered a resilient performance and Equity Derivatives, M&A and Securitized Products had solid performances in 1Q22, overall, this market environment, in combination with the cumulative effect of our newly defined risk appetite as executed during 2021, has led to an adverse impact on client activity in our Wealth Management division as well as a reduction in the level of capital markets issuances within our Investment Bank. Furthermore, the Investment Bank has relatively limited exposure to business areas, such as interest rate trading, which have benefited from these developments. We would expect these market conditions to persist in the coming months. In our Wealth Management business, while revenues should benefit later in the year from the higher interest rate environment, client risk appetite may remain subdued. Within the Investment Bank, while our M&A advisory pipeline is up both sequentially and on a year on year basis, and our leveraged finance business remains active, our ability to complete this client business is dependent on market conditions. Although the risk profile of our business is improving, our revenues will be adversely impacted by the cumulative reduction in our risk appetite in 2021 and by the exit from the majority of our Prime Service business. With regard to expenses, while variable compensation is expected to be subdued given the market environment, we expect increased cash accruals for compensation due to normalized deferral levels. Furthermore, we expect to see continued significant remediation spend in Risk, Compliance and Infrastructure. We continue to execute our expense saving programs and our outsourcing of our procurement function should generate significant savings; however, the bulk of the benefits from this broader program are only expected to be achieved in 2023.

06:19 EDT Taylor Morrison sees Q2 average active community count 310-315 - Home closings are expected to be between 3,000 to 3,200. Sees Q2 effective tax rate 24%.

06:12 EDT SoftBank Group selects Aryaka for its international SD-WAN Service, SD-CORE - Aryaka announced SoftBank has selected Aryaka's technology for its international SD-WAN Service, SD-CORE. The company will provide a flexible and highly secure network that will enable SoftBank to offer its customers the high-speed and stable data communications they demand. SoftBank is also tapping into Aryaka's new FlexCore, a global L3 private core that can supplement its best-in-class global L2 private core, both of which are interconnected to the company's nearly 40 high-performance points of presence that are strategically located around the world. This allows SoftBank to map customer sites to the private core of their choice whether it's based on performance or cost considerations or on the criticality of sites and applications. The company appreciates Aryaka's hybrid enterprise and cloud-friendly alignment that's able to map where enterprises are going with their traffic, connectivity, applications, and investment. In addition to a portal site that can centrally manage devices and networks, SoftBank will provide its customers with one-stop support for maintenance and operation after installation. Furthermore, SoftBank users will be able to build a more secure network as it can be linked with numerous cloud-based security services, including those provided by other security companies.

06:09 EDT BeiGene says Phase 3 trial of tislelizumab met endpoint - BeiGene announced the Independent Data Monitoring Committee determined at a pre-planned interim analysis that RATIONALE 306, a global Phase 3 trial of tislelizumab in combination with chemotherapy, had met the study's primary endpoint of overall survival in patients with previously untreated advanced or metastatic esophageal squamous cell carcinoma. The safety and tolerability profile for tislelizumab in combination with chemotherapy at this interim analysis was consistent with previous trials and no new safety signals were identified.

06:05 EDT Owens Corning sees near term U.S. residential housing market "strong" - Owens Corning stated that the key economic factors that impact the company's businesses are residential repair and remodeling activity, U.S. housing starts, global commercial construction activity, and global industrial production. In the near term, the company expects the U.S. residential housing market and global commercial and industrial markets to remain strong. The company continues to closely manage the ongoing impacts of inflation, supply chain disruptions, and the regional impacts of the COVID-19 pandemic on the business. For Q2, the company expects overall performance to result in net sales and adjusted EBIT growth for the quarter, versus the comparable quarter in the prior year. For 2022, the company expects general corporate expenses of $160M-$170M, interest expense $115M-$125M, tax rate on adjusted earnings 25%-27%.

06:04 EDT Spotify: Guidance reflects full closure of services in Russia - Guidance reflects the full closure of Spotify's services in Russia, which was completed on April 11, Spotify said.

05:46 EDT Walmart+ offers fuel discount to members through fuel station expansion - Walmart+ (WMT) is expanding its lineup of fuel stations. Walmart+ members will receive an instant discount of up to 10c on every gallon of fuel they purchase at participating fuel stations. With the addition of 12,000 Exxon and Mobil (XOM) locations across the country, a Walmart+ fuel discount is now available at more than 14,000 stations - a more than sixfold increase. Walmart+ members will save 10c per gallon at participating Exxon and Mobil locations, as well as 5c to 10c per gallon* at Walmart and Murphy USA stations. Member pricing is also available at more than 500 Sam's Club locations.

05:41 EDT 51job announces shareholder approval of merger with Garnet Faith - 51job announced that at an extraordinary general meeting of shareholders held, the company's shareholders voted in favor of, among other things, the proposal to authorize and approve the previously announced agreement and plan of merger, dated as of June 21, as amended by amendment No. 1 to agreement and plan of merger, dated as of March 1, between the company and Garnet Faith Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands, and the plan of merger required to be filed with the Registrar of Companies of the Cayman Islands, pursuant to which merger sub will merge with and into the company, with the company continuing as the surviving company, and to authorize and approve the consummation of any and all transactions contemplated by the Merger Agreement and the plan of merger, including the merger.

05:23 EDT Sound Financial Bancorp announces new $2M stock repurchase program - Sound Financial Bancorp announced that its board of directors approved an extension of its previously announced stock repurchase program authorizing the company to repurchase up to $2M of its outstanding shares of common stock during the period ending October 29. The new repurchase plan extends the October 2021 plan, which authorized the repurchase of up to $2M of the company's outstanding shares of common stock through April 25 of which approximately $352,00, or 8,668 shares, had been repurchased as of April 25. Under the plan, the company may purchase common stock from time to time in the open market, based on prevailing market prices, or in privately negotiated transactions, or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission.